![LifeWise Health Plan of Washington logo]

		RELATED POLICIES:
Effective Date:	**Jan. 3, 2025***	5.01.545 Tadalafil Products for Benign Prostatic Hyperplasia
Last Revised:	Sept. 10, 2024	
Replaces:	5.01.509 and 5.01.09	
*Click here to view the current policy.		

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING
RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY

∞   Clicking this icon returns you to the hyperlinks menu above.

Introduction

High blood pressure within the arteries that go to the lungs is known as pulmonary arterial hypertension. With this condition, the small arteries in the lungs become narrow or are completely blocked. Because it's difficult for blood to travel through them, the blood pressure in the lungs increases. The heart has to work harder to push blood through those arteries. This can lead to a weakened heart muscle and eventually heart failure. Treatment depends on the underlying cause of the high blood pressure and the severity of symptoms. There are several different drugs that can be used to manage the condition. Some drugs open narrowed blood vessels, others help relax the blood vessel walls, while yet others act on a specific substance in the walls of blood vessels. This policy describes when specific medications for pulmonary arterial hypertension may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a

service may be covered.

Policy Coverage Criteria

Therapy	Medical Necessity

Treatment of pulmonary arterial hypertension	**Combination therapy for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1) may be considered medically necessary when ALL of the following conditions are met:**
	• Individuals have failed to demonstrate an adequate response to a single medication
	AND
	• Medications are from different therapeutic classes
	AND
	• Each medication may be considered medically necessary for the treatment of PAH
	
	Combination therapy with tadalafil and ambrisentan as first-line treatment may be considered medically necessary for treatment naïve PAH individuals who are experiencing signs and symptoms of WHO functional class (FC) II or III
	
	Opsynvi (macitentan-tadalafil) may be considered medically necessary for the treatment of PAH WHO Group 1 in adults who are experiencing signs and symptoms of WHO functional class (FC) II or III
	
	The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1):
	• Phosphodiesterase-5 enzyme inhibitors
	    ○ Adcirca (tadalafil) (oral)
	    ○ Alyq (tadalafil) (oral); generic of Adcirca
	    ○ Revatio (sildenafil) (oral)
	    ○ Sildenafil 10 mg/mL (oral suspension); generic of Revatio
	    ○ Sildenafil 20 mg tablet (oral); generic of Revatio

∞

Therapy	Medical Necessity
	o Tadalafil 20 mg tablet (oral); generic of Adcirca
	o Tadliq (tadalafil) 20 mg/5 mL (oral suspension)
	o Liqrev (sildenafil) 10 mg/mL (oral suspension)
	• Soluble guanylate cyclase (sGC) stimulators
	o Adempas (riociguat) (oral)
	• Prostacyclins
	o Flolan (epoprostenol) (IV infusion)
	o Orenitram (treprostinil) (oral)
	o Treprostinil (SC infusion, IV infusion)
	o Tyvaso (treprostinil) (inhalation solution via nebulizer)
	o Tyvaso DPI (treprostinil) (inhalation via dry powder)
	o Uptravi (selexipag) (oral, IV infusion)
	o Veletri (epoprostenol) (IV infusion)
	o Ventavis (iloprost) (inhalation via nebulizer)
	• Endothelin receptor antagonists
	o Generic ambrisentan (oral)
	o Generic bosentan (oral)
	o Letairis (ambrisentan) (oral)
	o Opsumit (macitentan) (oral)
	o Tracleer (bosentan) (oral)
	Remodulin (treprostinil injection; for SC or IV infusion) may be considered medically necessary for the treatment of pulmonary arterial hypertension in individuals classified as World Health Organization Group 1 when:
	Individual has tried and had an inadequate response or intolerance to generic trepostinil injection (SC or IV infusion)
	Winrevair (sotatercept-csrk) may be considered medically necessary for the treatment of individuals with pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 when all the following are met:
	• Individual is aged 18 years or older
	AND
	• Individual has been diagnosed with PAH WHO Group 1
	AND

Therapy	Medical Necessity
	• Individual is experiencing signs and symptoms of WHO functional class (FC) II or III
	AND
	• Individual has a pulmonary vascular resistance (PVR) greater than or equal to 5 Wood units from right heart catheterization (RHC)
	AND
	• Individual has a pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg from RHC
	AND
	• Individual has tried and had an inadequate response to an endothelin receptor antagonist (e.g., bosentan, ambrisentan, or macitentan)
	AND
	• Individual has tried and had an inadequate response to a phosphodiesterase-5 (PDE5) inhibitor (e.g., sildenafil or tadalafil) OR a soluble guanylate cyclase (sGC) stimulator (e.g., riociguat)
	AND
	• Individual will continue current PAH treatments unless not tolerated
	AND
	• Individual does not have any of the following:
	o Uncontrolled systemic hypertension
	o Left ventricular ejection fraction of < 45%
	o History of untreated portal hypertension, liver disease, untreated obstructive sleep apnea, or symptomatic coronary disease (e.g., heart failure or stroke)
	o Platelet count less than 50,000/mm^3
	AND
	• Winrevair (sotatercept-csrk) is prescribed by or in consultation with a cardiologist or pulmonologist
	Use of Adcirca (tadalafil 20 mg), Alyq (tadalafil 20 mg), Revatio (sildenafil 20 mg; sildenafil 10 mg/mL), sildenafil 20 mg tablet (generic of Revatio), sildenafil 10 mg/mL suspension (generic of Revatio), tadalafil 20 mg tablet (generic of

Therapy	Medical Necessity
	Adcirca), Tadliq (tadalafil 20 mg/5 mL), or Liqrev (sildenafil 10mg/mL) to treat erectile dysfunction, or other uses, is considered investigational.
Treatment of chronic thromboembolic pulmonary hypertension	Adempas (riociguat) may also be considered medically necessary for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH/ WHO Group 4) in individuals who are not surgical candidates, those who have inoperable CTEPH, or those with recurrent or persistent CTEPH after surgical treatment.

Therapy	Investigational
Other advanced therapies	Use of other advanced therapies for the pharmacologic treatment of pulmonary arterial hypertension (PAH/ WHO Group 1), including but not limited to Gleevec (imatinib), simvastatin, and atorvastatin, is considered investigational.
Treatment of any other conditions	The use of Adempas (riociguat) is considered investigational for the treatment of any other conditions or subtypes of PH, except WHO Groups 1 and 4. The use of Tyvaso (treprostinil) and Tyvaso DPI (treprostinil) is considered investigational for the treatment of any other conditions or subtypes of PH, except WHO Groups 1 and 3.
Treatment of non-PAH PH conditions	The use of Adcirca (tadalafil), Alyq (tadalafil), ambrisentan, bosentan, Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil), Remodulin (treprostinil), Revatio (sildenafil), sildenafil 20 mg tablet (generic of Revatio), sildenafil 10 mg/mL suspension (generic of Revatio), tadalafil 20 mg tablet (generic of Adcirca), Tadliq (tadalafil), Liqrev (sildenafil), Tracleer (bosentan), treprostinil, Uptravi (selexipag), Veletri (epoprostenol), Ventavis (iloprost), or Winrevair (sotatercept-csrk) is considered investigational for the treatment of non-PAH PH conditions (WHO Groups 2-5), including but not limited to: • Pulmonary hypertension associated with left heart diseases • Pulmonary hypertension associated with lung diseases and/ or hypoxemia (including chronic obstructive pulmonary disease)

Therapy	Investigational
	• Pulmonary hypertension due to chronic thrombotic and/or embolic disease • Miscellaneous group (sarcoidosis, histiocytosis X and lymphangiomatosis)

Length of Approval	
Approval	**Criteria**
Initial authorization	**All drugs listed in policy may be approved up to 12 months.**
Re-authorization criteria	**Future re-authorization of all drugs listed in policy may be approved up to 12 months as long as the drug-specific coverage criteria are met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.**

Documentation Requirements
The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:
• Office visit notes that contain the diagnosis, relevant history, physical evaluation and medication history

Coding

Code	Description
HCPCS	
J1325	Injection, epoprostenol (Use to report Flolan and Veletri), 0.5 mg
J3285	Injection, treprostinil (Remodulin), 1 mg
J3490	Unclassified Drugs (Use to report Uptravi and Revatio)
J3590	Unclassified biologics (used to report Winrevair)
J7686	Treprostinil (Tyvaso), inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, 1.74 mg

Code	Description
J8499	Prescription drug, oral, nonchemotherapeutic, NOS (Use to report Liqrev and Opsynvi)
K0455	Infusion pump used for uninterrupted parenteral administration of medication (e.g. epoprostenol or treprostinil)
Q4074	Iloprost, inhalation solution, FDA-approved final product, noncompounded, administered through DME, up to 20 mcg

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Benefit Application

Epoprostenol IV, treprostinil SC/IV, and Uptravi (selexipag) IV are managed under the medical benefit.

Bosentan, ambrisentan, macitentan, riociguat, iloprost, treprostinil oral/DPI, selexipag, and sildenafil are managed under the pharmacy benefit.

Sotatercept is managed under the pharmacy and medical benefit.

Individuals treated with infusion pumps may require a back-up pump. However, the cost of a back-up pump may be included in the home infusion therapy charges or in the HCPCS code (see **Coding** section).

Evidence Review

Description

Pulmonary hypertension (PH) refers to the presence of abnormally high pulmonary vascular pressure. A subset of individuals is considered to have pulmonary arterial hypertension (PAH), a rare and debilitating disease associated with progressive right ventricular dilation and low cardiac output. Several advanced therapies, including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 (PDE5) inhibitors, and a soluble guanylate cyclase

stimulator are available to treat PAH. Another subset of individuals is considered to have chronic thromboembolic pulmonary hypertension (CTEPH), characterized by residual organized thrombi obstructing the pulmonary vasculature. Most individuals have a history of acute pulmonary embolism. Standard treatment for CTEPH is pulmonary endarterectomy. The soluble guanylate cyclase stimulator, riociguat, is the only medication currently US Food and Drug Administration (FDA)–approved to treat CTEPH.

For individuals who have PAH and inadequate response to monotherapy who receive add-on combination therapy using 2 drug classes FDA approved for treatment of PAH, the evidence includes RCTs and meta-analyses. Relevant outcomes are overall survival, functional outcomes, hospitalizations, and treatment-related morbidity. The most recent and comprehensive meta-analysis of RCTs was published in 2016. It included 17 RCTs comparing add-on combination therapy with monotherapy with at least 12 weeks of follow-up. The meta-analysis found significantly lower rates of clinical worsening and hospitalizations with add-on combination therapy, but mortality rates did not differ significantly between groups. In all RCTs selected for the 2016 meta-analysis, the combination therapy involved different drug combinations from different classes, although the specific combination of riociguat and phosphodiesterase type 5 inhibitors is contraindicated. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have PAH who receive initial combination therapy using 2 drug classes FDA approved for treatment of PAH, the evidence includes 2 RCTs. Relevant outcomes are overall survival, functional outcomes, hospitalizations, and treatment-related morbidity. In the first study (AMBITION trial), among individuals in the primary analysis set, there was a significantly lower rate of clinical failure at 6 months in the combination therapy group than in the monotherapy group. Clinical failure was defined as a complex composite endpoint that included death, hospitalizations, functional improvement, and other measures of disease progression. Study limitations include change in enrollment criteria during the trial and use of a complex composite outcome with multiple components. The other RCT did not find significant differences in outcomes between a group receiving initial combination therapy and the group receiving monotherapy at 16 weeks; this study had a small sample size and might have been underpowered to assess secondary outcomes. Multiple reviews of the AMBITION trial with an emphasis on functional improvement (6MWT) have led to guideline recommendations for making ambrisentan plus tadalafil an appropriate initial treatment option. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have inoperable CTEPH or PH after surgery who receive a soluble guanylate cyclase stimulator (e.g., riociguat), the evidence includes 1 RCT. Relevant outcomes are overall

survival, functional outcomes, hospitalizations, and treatment-related morbidity. The double-blind RCT found that functional outcomes at 16 weeks improved significantly more in the group receiving riociguat than placebo. Both groups had a high proportion of adverse events, and 1 death was attributed to riociguat. In an extension study, the estimated 1-year survival rate was 97%. Thirteen deaths occurred, none of which were attributed to study medication. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have operable CTEPH who receive perioperative prostacyclin analogues, endothelin receptor antagonists, or riociguat, the evidence includes 1 small RCT on bosentan, retrospective noncomparative studies on epoprostenol and iloprost, and no trials on riociguat. Relevant outcomes are overall survival, functional outcomes, hospitalizations, and treatment-related morbidity. The few studies, with small numbers of individuals and limited comparative data, do not provide sufficient evidence to determine whether mortality and pulmonary vascular resistance are reduced with any of these medications. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Background

Pulmonary Hypertension (PH)

The World Health Organization (WHO) classifies individuals with PH into 5 groups based on the etiology of the condition. These groups differ in their clinical presentation, diagnostic findings, and response to treatment.

Classification

The 2013 WHO classification of PH, which is based on the consensus of an international group of experts at the Fifth World Symposium on Pulmonary Hypertension, is the most widely used system in clinical care and research. There are 5 WHO categories of PH based on the etiology of the pulmonary hypertension:

- Group 1: Pulmonary arterial hypertension (PAH)

- Group 2: PH due to left heart disease

- Group 3: PH due to chronic lung disease and/or hypoxemia

- Group 4: PH due to chronic thromboembolic disease (chronic thromboembolic pulmonary hypertension [CTEPH])

- Group 5: PH due to mixed or uncertain causes.

For each category, there are numerous subcategories indicating more specific disease etiologies. For example, in WHO group 1, the most common subcategory is idiopathic PAH, which is a disorder of unknown etiology categorized by abnormal proliferation of blood vessels in the pulmonary arterial system. Other classification systems, such as those developed by the American College of Cardiology Foundation and American Heart Association, are very similar but have differences in the subcategories of group 1.

Disease Description

Pulmonary hypertension is defined as increased arterial pressure in the lung vasculature. Increased pulmonary pressure can be caused by primary abnormalities in the pulmonary vascular system; it can also be caused by other abnormalities in the cardiac or pulmonary organs, which may lead to secondary elevations in pulmonary arterial pressure. A definitive diagnosis of PH is usually made following measurement of pulmonary arterial pressure by right heart catheterization. A pulmonary arterial pressure of at least 25 mmHg confirms the diagnosis.

Clinical symptoms of PH are related to right-sided heart failure and impaired oxygen delivery by the lungs. Warning signs are nonspecific but often present as a constellation of symptoms including dyspnea on exertion, fatigue, weakness, and syncope. High pulmonary pressures lead to increased work of the right ventricle. This chronic hemodynamic overload leads to low cardiac output and progressive right ventricular dilatation. In advanced disease, signs of right-sided heart failure occur (e.g., abdominal distension, hepatic congestion, pedal edema). Without treatment, the disease is progressive and eventually fatal; however, the natural history and rapidity of progression is variable. Premature death most commonly results from complications of right heart failure.

There are also differences in the pathophysiology, clinical manifestations, and natural history of each PH category. Only categories relevant to this evidence review (WHO groups 1 [PAH] and 4 [CTEPH]) are discussed herein.

The WHO further classifies individuals with pulmonary hypertension based on functional ability:

- Class I: No limitations with ordinary physical activity

- Class II: Ordinary physical activity results in symptoms. Comfortable at rest.

- Class III: Less than ordinary physical activity results in symptoms. Comfortable at rest.

- Class IV: Inability to perform any physical activity without symptoms. Symptoms present at rest.

Medical Management of PAH

Conventional therapies considered in all individuals with PH regardless of etiology include medications to treat heart failure (diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, digoxin), oxygen therapy, and exercise. Lung transplantation and combined heart-lung transplantation have been performed in individuals with PH that is refractory to medical management. There are also specific therapies for each WHO group. For example, anticoagulation is a treatment option in WHO groups 1 and 4, and both anticoagulation and surgical thrombectomy are treatment options for appropriate individuals in group 4.

Advanced pharmacologic therapies for PH are defined as newer specialty pharmacy drugs specifically intended to impact the natural history of PH, rather than treat disease manifestations. These specialty drugs can be administered as single agents or in various combinations. Advanced pharmacologic therapies are FDA approved for treatment of PH groups 1 and 4.

Chronic Thromboembolic PH

Disease Description

CTEPH primarily occurs after acute or chronic pulmonary embolism. Progressive pulmonary vascular remodeling (thrombi organization, fibrous stenosis, and microvascular changes) obstructs pulmonary arteries, leading to PH and right heart failure. Estimated CTEPH incidence among individuals who survive an acute pulmonary embolism ranges from 0.6% to 3.8%. However, many individuals have no clinical history of pulmonary embolism, and CTEPH is likely underdiagnosed. Additional risk factors include splenectomy, chronic inflammatory states, and hypercoagulability due to the presence of anticardiolipin antibody or elevated factor VIII levels. Diagnosis is made by ventilation-perfusion scan showing large areas of mismatch (segmental or larger). Pulmonary angiography confirms the diagnosis and indicates operability (i.e., the extent of proximal and distal disease).

Hemodynamic Derangement

CTEPH is characterized by a mean pulmonary artery pressure greater than 25 mm Hg. European guidelines also require pulmonary capillary wedge pressure of 15 mm Hg or less and PVR greater than 2 Wood units. In individuals with poor hemodynamics (e.g., pulmonary artery pressure greater than 50 mm Hg) who are eligible for pulmonary endarterectomy, pretreatment with intravenous epoprostenol is recommended to improve surgical outcomes.

Medical Management of CTEPH

Individuals with CTEPH are treated with diuretics and oxygen as needed and with extended or lifelong anticoagulant therapy. Eligible individuals undergo pulmonary endarterectomy, which may be curative. Current guidelines recommend medical treatment using PAH therapies when pulmonary endarterectomy is contraindicated (due to significant distal disease or comorbidity) and when pulmonary artery pressures remain elevated after pulmonary endarterectomy (due to residual distal pathology).

The only medication currently FDA-approved for treatment of CTEPH is riociguat. Riociguat is a first-in-class oral soluble guanylate cyclase stimulator. Riociguat stimulates soluble guanylate cyclase both directly and indirectly, by increasing sensitivity of the enzyme to nitric oxide. Thus, riociguat may be effective in conditions in which endogenous nitric oxide (a vasodilator) is depleted.

Rationale

Research Issues

Editorial critiques of the available literature have raised questions about the study endpoints selected, which are often short-term measures that are insufficient for addressing the mechanism of disease, optimizing treatment by individual population, and making meaningful comparisons between therapies. Studies are short in duration and compare outcomes that reflect symptomatic improvement (e.g., 6-minute walk distance or functional class) but not disease status (such as vasculature remodeling) or survival. Studies also need to address the durability of these outcomes. However, designing long-term (1 year or more) studies with survival as an endpoint may raise additional issues, including potential ethical questions.

Additionally, some authors have questioned the utility of the 6-minute walk distance (6MWD) as an intermediate clinical outcome in therapeutic pulmonary arterial hypertension (PAH) trials. It is unclear whether change in 6MWD is associated with clinical outcomes (e.g., death, lung transplantation, hospitalization due to worsening PAH, or worsening right heart failure), or whether there is a threshold above and below at which risk for adverse outcomes substantially changes. Two groups attempted to validate the 6MWD and to define a minimal important difference (MID) using different methods. Gabler et al. examined correlations between 6MWD and clinical events in order to establish a threshold that would indicate a significant change in the probability of such events. A significant threshold effect was observed at 41.8 meters. However, the authors noted that "change in 6MWD does not explain a large proportion of the treatment effect, has only modest validity as a surrogate end point for clinical events, and may not be a sufficient surrogate end point." Mathai and colleagues used anchor- and distribution-based methods and reported MIDs of 38.6 meters and 25.1-38.5 meters, respectively. The mean of these values was 33 meters, which the authors considered a consensus MID. A 2012 meta-analysis of 22 randomized controlled trials (RCTs) that assessed 6MWD in individuals with PAH and reported clinical outcomes found no relationship between changes in 6WMD and clinical outcomes. All 3 of these analyses were based on trials of short duration (e.g., 12 weeks) and in treatment-naïve individuals; it may be that the utility of the 6MWD is limited to such trials.

PAH Monotherapy Using Prostanoids, Endothelin-Receptor Antagonists or Phosphodiesterase Type-5 (PDE5) Inhibitors, or a Soluble Guanylate Cyclase Stimulator (Riociguat)

Several meta-analyses that pool the findings of studies evaluating the efficacy of PAH treatments have been published. In 2013, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review of the screening, management, and treatments of PAH. McCrory et al. searched the literature through July 2012 using broad inclusion criteria (diagnosis of PAH in individuals of any age; RCTs or observational studies; all sample sizes). They identified 27 RCTs (3,587 individuals) and 9 observational studies that evaluated the comparative effectiveness and safety of monotherapy or combination therapy for PAH. Data from the observational studies was considered unusable. Twenty-two RCTs compared a single drug (i.e., monotherapy) to placebo or standard therapy, defined as supportive treatment (diuretics, oxygen, digoxin, and/or oral anticoagulants) with or without calcium channel blockers (CCBs); 8 studied prostanoids, 8 studied endothelin-receptor antagonists, and 6 studied PDE5 inhibitors. All individuals were adults. Median trial duration was 12 weeks (range 4-24). Based on low strength of evidence, prostanoids were associated with lower mortality

compared with standard therapy/placebo (odds ratio [OR]: 0.52 [95% confidence interval (CI): 0.29-0.95]). Evidence for endothelin receptor antagonists and PDE5 inhibitors was insufficient to form a conclusion for this outcome. Moderate strength of evidence for each drug class supported an association with improved 6-minute walk distance (6MWD); treatment effects (mean difference in distance walked, intervention – standard therapy/placebo) were 27.9 meters (95% CI: 10.3-45.4) for prostanoids, 39.9 meters (95% CI: 21.4-58.4) for endothelin-receptor inhibitors, and 38.9 meters (95% CI: 22.0-55.9) for PDE5 inhibitors. Endothelin-receptor antagonists and PDE5 inhibitors were associated with lower incidences of hospitalization based on moderate strength of evidence for each drug class; ORs were 0.34 (95% CI: 0.17- 0.69) and 38.9 (95% CI: 22.0- 55.9). Evidence for prostanoids was insufficient to form a conclusion for this outcome. Low strength of evidence for each drug class supported an association with improvements in most hemodynamic measures (pulmonary vascular resistance [PVR], mean pulmonary artery pressure, and cardiac index). However, the clinical significance of the observed treatment effect magnitudes is unclear. Among commonly reported adverse events, high strength of evidence supported a greater incidence of jaw pain and cough with aerosolized prostanoid than with placebo. Moderate strength of evidence supported a greater incidence of headache and flushing with PDE5 inhibitors compared with standard therapy/placebo. The incidence of flushing was greater with aerosolized prostanoids than with standard therapy/placebo, based on moderate strength of evidence.

A 2013 Cochrane review by Liu et al. assessed the efficacy of endothelin receptor antagonists for the treatment of individuals with PAH. A literature search through December 2011 identified 12 RCTs (1,471 individuals), 11 of which were placebo controlled. The 12th RCT was a head-to-head comparison of bosentan and sildenafil in 26 individuals. Seven of 12 trials assessing bosentan comprised 38% of the total individual sample, 2 trials assessing ambrisentan comprised 27%, and 3 trials assessing sitaxsentan comprised 35%. Sitaxsentan is a selective endothelin receptor antagonist (like ambrisentan) that was withdrawn worldwide in 2010 due to fatal hepatotoxicity. Pooled results showed improved outcomes with endothelin-receptor antagonists compared to placebo in 6MWD (mean difference 33.7 meters [95% CI: 24.9-42.5]), proportion of individuals with improved WHO or NYHA functional class (OR: 1.6 [95% CI: 1.2-2.1]), proportion of individuals with deteriorated functional class (OR: 0.3 [95% CI: 0.2-0.4]), and hemodynamic parameters (mean pulmonary artery pressure, pulmonary vascular resistance, and cardiac index). Based on 22 events in 1,201 individuals, the reduction in mortality with endothelin receptor antagonists was not statistically significant (OR: 0.57 [95% CI: 0.26, 1.24]).

In 2009, Galie et al. in Italy published a meta-analysis of RCTs examining approved medications i.e., prostanoids, endothelin-receptor antagonists, and PDE5 inhibitors for treating PAH. The primary analysis included only studies with a placebo-comparator arm; a sensitivity analysis also included studies comparing 2 active treatment arms. The main outcome measure was all-cause

mortality. Twenty-one trials were included in the primary analysis (n=3,140), and 2 additional studies (n=59) were included in the sensitivity analysis. The average duration of the trials was 14.3 weeks. All-cause mortality rate in the control group was 3.8%. Active treatments were associated with a reduction in mortality of 43%; the sensitivity analysis confirmed a reduction in mortality of 38%. The authors concluded that the results of this meta-analysis suggest an improvement of survival in the individuals treated with the targeted therapies approved for PAH. The limitations of the meta-analysis include the prolonged period of time between the first and last RCT (about 18 years), the different duration of the trials (ranging from 8–36 weeks), the lack of blinding in some studies, the pooling of multiple active treatment arms, and potential heterogeneity in the conduct of the trials. The meta-analysis included studies with compounds that were eventually not approved because of lack of efficacy and different doses of approved therapies that were not approved because they were less effective or had increased adverse effects.

Two meta-analyses published in 2010, were similar in scope and design to the 2009 meta-analysis by Galie et al. All 3 were limited to RCTs in individuals with PAH, had all-cause mortality as the primary outcome and evaluated the same classes of medications, prostanoids, endothelin-receptor antagonists, and PDE5 inhibitors. Ryerson and colleagues searched the literature through November 2009. Their eligibility criteria included RCTs in adults with PAH, and they further required that studies have a follow-up of at least 8 weeks, be double-blind, and be placebo-controlled (except for studies on intravenous [IV] medication use). They included both studies that compared one medication to placebo (monotherapy), as well as studies that added a second medication versus placebo to a baseline medication (combined treatment); the latter were categorized by the class of the medication in the study that was under investigation. Twenty-four trials met the inclusion criteria. This included 11 on prostanoids, 8 on endothelin-receptor antagonists, and 3 on PDE5 inhibitors. The investigators did not pool studies across classes of medications. There was a statistically significant reduction in all-cause mortality in a meta-analysis of the studies on prostanoids, but not studies on endothelin-receptor antagonists, or PDE5 inhibitors. The pooled analysis of prostanoid trials found a 51% mortality reduction (95% confidence interval [CI]: 18-71%). Meta-analyses of each of the 3 classes of medication found statistically significant improvement in exercise capacity, the primary outcome in most of the studies. In pooled analyses, prostanoids were associated with a mean placebo-corrected improvement in 6-minute walk distance of 29 meters (95% CI: 18-41 meters), endothelin-receptor antagonists were associated with improvement of 38 meters (95% CI: 27 to 49 meters), and PDE5 inhibitors were associated with an improvement of 34 meters (95% CI: 23-49 meters).

The other 2010 meta-analysis, by Macchia et al., searched the literature through April 2009 and, like the Ryerson et al. study, included RCTs on adults with PAH. However, in this study, both open and blinded trials were included, and eligibility was not limited by type of control group

(e.g. placebo). Combination medication studies were treated in the same manner as in Ryerson et al., discussed above. Twenty-six trials met eligibility criteria. Of these, 9 were on prostanoids, 8 on endothelin-receptor antagonists, and 8 on PDE5 inhibitors. In a meta-analysis of studies on all 3 classes of medications combined (23 studies), there was a statistically significant reduction in total mortality of 39% (2-62%) in the treatment group compared to controls. However, when studies on each class of medication were examined separately, there were no significant reductions in mortality. For example, the pooled analysis of studies on prostanoids found a nonsignificant 34% reduction in mortality; the 95% confidence interval was consistent with a 64% decrease in mortality to a 21% increase. The mortality reduction seemed confined to studies with more seriously ill study populations. With all classes of medication combined, there was a significant reduction in all-cause mortality when findings from trials with a median mortality of above 2% were pooled; mortality reduction was 49% (95% CI: 12-70%). There was no significant reduction in mortality in studies that had lower mortality rates. In addition, there was a significant mortality reduction in studies that included individuals with functional class IV (42%, 95% CI: 4-65%) but not studies that excluded these individuals. The authors also pooled study findings on change in exercise capacity and pulmonary vascular resistance (PVR). They found small but statistically significant improvement in exercise capacity and PVR. This was true for analyses pooling all studies, as well as those limited to one class of medication. For example, a pooled analysis of endothelin-receptor antagonists found a mean increase in the 6-minute walk distance of 46 meters (95% CI: 38-54 meters) with treatment versus control. A meta-analysis of prostanoid studies found a mean fall in PVR of 4.24 mm Hg (95% CI: fall of 3.49-5.00 mm).

The all-cause mortality reduction with all medications combined in the Macchia et al. (2010) meta-analysis, 39%, is similar to that found by Galie et al. (2009), 43%. Macchia and colleagues, however, urge caution when interpreting this finding, since none of the individual classes of medication were found to reduce mortality. Moreover, they question the validity of combining studies of pharmacologic treatments that have completely different modes of action and suggest that the finding of mortality reduction be tested in prospective clinical trials.

Representative randomized trials and observational studies evaluating specific medications are described below.

Epoprostenol

The original approval of epoprostenol from the FDA was based on a 12-week trial of 81 individuals with New York Heart Association (NYHA) Class III or Class IV primary pulmonary hypertension who were randomized to receive either epoprostenol or conventional medical

management. As compared to conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in individuals with severe primary pulmonary hypertension. In 1998, McLaughlin and colleagues reported on a case series of 27 individuals treated with epoprostenol who were followed up for a mean of 16 months. All individuals had improvements in symptoms such as NYHA classification and exercise duration. While pulmonary vascular resistance declined only 23% acutely in response to a test dose of adenosine (another vasodilator), over long-term follow-up the vascular resistance fell by 53%. These results suggest that the beneficial effects of epoprostenol are not solely related to vasodilation but perhaps are related to anticoagulant and endothelial cytoprotective effects. McLaughlin and colleagues subsequently reported survival data for those receiving epoprostenol. A total of 162 consecutive individuals diagnosed with primary pulmonary hypertension (PHTN) were treated with epoprostenol and followed up for a mean of 36.3 months. Observed survival at 1, 2, and 3 years was 87.8%, 76.3%, and 62.8%, which was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4%, all respectively, based on historical controls.

In 2000, epoprostenol received additional FDA approval as a treatment for pulmonary hypertension (PH) associated with the scleroderma spectrum of disease, based in part on the following data. Humbert et al. reported on an uncontrolled case series of epoprostenol in 17 individuals with PHTN associated with either scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), or Sjogren's syndrome. Individuals were followed up from 14 to 154 weeks. After 6 weeks, exercise capacity improved in 15 of 17 individuals; the remaining 2 individuals died of pulmonary edema or sepsis. During the long-term follow-up, an additional 5 individuals died, 2 individuals underwent successful lung transplantation, and 7 of the remaining 8 individuals had a persistent clinical improvement. Badesch and colleagues reported on a study that randomized 111 individuals with pulmonary hypertension (PH) related to scleroderma to receive either conventional therapy or conventional therapy in addition to epoprostenol therapy. The primary outcome measure was exercise capacity. A significant improvement in exercise capacity was noted in the epoprostenol group compared to the control group, for whom exercise capacity actually decreased. Cardiopulmonary hemodynamics also improved significantly in the treatment group compared to the control group. A total of 38% of individuals in the treatment group reported improvements in NYHA classification, compared to none in the control group. Four deaths occurred in the epoprostenol group compared to 5 in the control group, although it should be noted that the study was not adequately powered to detect a significant difference in survival.

Rosenzweig et al. reported on a case series of 20 individuals with PH secondary to congenital heart disease who had failed to improve clinically with conventional therapy. Although none of the individuals experienced a decrease in pulmonary artery pressure in response to

epoprostenol infusion, long-term therapy was associated with a 21% reduction in pulmonary artery pressure. In addition, NYHA classification improved from a mean of 3.2 to 2.0. A nonsignificant increase occurred in exercise capacity. Treatment with Flolan (epoprostenol) and Veletri (epoprostenol) requires 3 steps as follows:

- Initial dose-ranging study, which is typically performed as an inpatient. The pulmonary capillary wedge pressure is monitored, and the infusion rate of the drug is increased until dose-limiting pharmacologic effect such as nausea, vomiting, or headache is elicited. Some practitioners may consider the initial dose-ranging study optional.

- Insertion of central venous catheter and attachment to portable infusion pump. Since rebound pulmonary hypertension may recur if the drug is abruptly withdrawn, the drug labeling advises that all individuals should have access to a backup infusion pump and intravenous infusion set.

- Ongoing maintenance of portable infusion pump and treatment of complications related to the pump. Complications include catheter thrombosis, sepsis, and pump malfunction. In the clinical trials, a cold pouch and frozen gel packs were used to facilitate extended use at ambient temperatures.

Treatment with iloprost requires the use of a specialized dispensing device.

For combination treatment, riociguat should not be combined with a phosphodiesterase type 5 inhibitor (sildenafil, tadalafil, or vardenafil).

Remodulin (treprostinil)

Infused

The FDA approval of Remodulin (treprostinil) was based in part on 2 randomized, placebo-controlled double-blind studies of subcutaneous infusion of treprostinil in 470 individuals with PAH, either idiopathic or associated with connective tissue disease or congenital systemic-to-pulmonary shunts and a subgroup analysis of 90 individuals with PAH associated with connective tissue disease. Endpoints, measured at 12 weeks, included exercise capacity (as measured by the 6-minute walk test [6MWT]), dyspnea, and hemodynamic effects. There was a median 16-meter improvement in the 6MWT, which although statistically significant was not as great as that noted for epoprostenol. Individuals who were more compromised at baseline had the greatest improvements, and thus the lower median improvement may be related to the inclusion of less severe individuals (i.e., Class II) in this trial. There were no statistically significant

differences in pretreatment and post-treatment hemodynamic variables between individuals with different connective tissue diseases.

A cohort study of long-term survival was identified, which compared survival of individuals (idiopathic PAH or associated with connective tissue, congenital heart disease, portal hypertension, or human immunodeficiency virus [HIV]) treated with treprostinil (up to 4 years) with predicted survival using a National Institutes of Health (NIH) registry equation or untreated individuals from registry data. Treprostinil survival among 860 individuals was 87–68% over 1–4 years, noting that 59% of individuals discontinued treatment due to adverse events (39%), death (27%), clinical deterioration (23%), and other reasons (withdrew consent, transplantation, protocol violation, and loss to follow-up; 11%). Sensitivity analyses found no differences between those discontinuing due to site pain reaction and individuals who did not discontinue; however, selection bias due to censoring is possible and could bias the results in favor of treprostinil survival. Among 332 individuals for whom predicted survival could be calculated (using the NIH registry equation), treprostinil treatment resulted in 91% and 72% survival at 1 and 4 years compared to predicted survival of 69% and 38%, respectively.

Findings of a 12-week randomized placebo-controlled trial evaluating intravenous treprostinil in treatment-naïve individuals with PAH were published in 2010 by Hiremath and colleagues. The study, conducted in India, randomized 45 individuals, one of whom died during catheter placement. Due to safety concerns, recruitment was stopped early after these 45 individuals had enrolled; an intention-to-treat analysis was performed on these individuals' outcomes data. Forty-two of the 44 individuals who received study medication had idiopathic PAH, and 2 had PAH associated with collagen vascular disease. Forty-two of 44 individuals had NYHA Class III disease and 2 had Class IV disease. The initial dose of medication was 4 ng/kg/min treprostinil or an equivalent volume of placebo. After the first week, dose increases up to 8 ng/kg/min weekly were allowed, up to a maximum of 100 ng/kg/min. Thirty-one of 45 (67%) randomized individuals completed the study; 6 individuals (3 in each group) died during the 12-week follow-up period. The mean treprostinil dose at 12 weeks was 72 ng/kg/min, and the mean placebo dose was 80 ng/kg/min. The primary efficacy outcome was change in the 6-minute walk distance (6MWD) from baseline to 12 weeks. The mean baseline 6MWD was 292 meters in the treprostinil group (n=30) and 231 in the placebo group (n=14). The mean change was an increase of 67.2 meters in the treprostinil group and a decrease of 25.5 meters in the placebo group; the difference between groups was statistically significant, p=0.022. This represents a placebo-corrected difference of a mean of 92.7 meters (standard error [SE]=42.0). The median placebo-corrected difference between groups was 83 meters (95% confidence interval [CI]:7-187 meters, p=0.008) There were also statistically significant differences on other outcomes, favoring the treprostinil group. For example, there was a mean decrease of 1.7 points on the Borg

dyspnea scale in the treprostinil group and a mean increase of 0.4 points in the placebo group, p=0.009. (A higher score on the Borg scale represents more dyspnea.)

Inhaled

One small uncontrolled series reported treatment of PAH in children. Krishnan et al performed a retrospective cohort study of 29 children (median age 12 years, range 3.2-19) who received inhaled Tyvaso (treprostinil) for 6 weeks or longer. Children were individuals at one of 2 large pediatric PH centers (Columbia University Medical Center, New York and Children's Hospital, Colorado). Indications for initiation of inhaled treprostinil therapy included symptomatic PAH despite background therapy or as a strategy to transition individuals off parenteral prostanoids. Twenty-six individuals were on PDE5 inhibitors, 22 were on endothelin-receptor antagonists, 12 were on prostanoids, 18 were on dual therapy, and 5 were on triple therapy. Treprostinil was started at 3 breaths (6 mcg/breath) 4 times daily and titrated to a maximum of 9 breaths 4 times daily in 20 individuals. The maximum dose for 9 younger children and individuals experiencing side effects was 4-8 breaths 4 times daily. Mean treatment duration was 16 months. Four individuals discontinued treatment after 4 months due to progressive pulmonary symptoms, and 1 individual each required dose reduction due to nausea and hypotension. Common adverse effects were cough, sore throat, headache, and nausea. In 13 individuals for whom baseline and follow-up data were available, 6MWD improved from 456±72 meters to 498±70 meters. WHO functional class improved in 19 individuals and was unchanged in 10. Improvements in hemodynamic parameters (right atrial pressure, pulmonary artery pressure, systemic arterial pressure, PVR, systemic vascular resistance) were observed in 8 individuals for whom baseline and follow-up data were available.

Oral

FDA approval of oral Orenitram (treprostinil) for the treatment of PAH (WHO Group 1) was based in part on 3 short-term RCTs: FREEDOM-C and FREEDOM-C2 in individuals receiving background PAH therapy, and FREEDOM-M in previously untreated individuals.

FREEDOM-M (N=349 randomized; 228 analyzed) was a 12-week, multicenter, double-blind, placebo-controlled RCT of oral treprostinil monotherapy. Eligible individuals had PAH; were not currently receiving PDE5-inhibitors, endothelin receptor antagonists, or prostacyclin; and had a minimum 6MWD of 100 meters. Individuals were randomized 2:1 to oral treprostinil or matching placebo. Treprostinil was started at 1 mg twice daily and increased as tolerated every 3 days, but based on the FREEDOM-C trial (described next); starting dose was lowered to 0.25 mg twice

daily. The primary end point was change from baseline 6MWD at 12 weeks; the trial was powered to detect a 45-meter between-group difference in 6MWD at 12 weeks. Results were analyzed for only 65% of individuals in each group; individuals who had access to the 0.25 mg treprostinil dose at the time of randomization and received at least 1 dose of study drug were included (total N=228). For this group, mean age was 39 years, and 71% of individuals were from India or China. PAH etiologies were idiopathic or heritable (74%), collagen vascular disease (19%), congenital heart defect (6%), and HIV (1%). Functional status was predominantly WHO class II (33%) and class III (66%). Mean baseline 6MWD was 330 meters. Twenty-six individuals (17%) receiving oral treprostinil and 11 individuals (14%) receiving placebo discontinued study drug; discontinuations due to adverse events occurred in 6 individuals and 2 individuals, respectively. Mean dose of treprostinil at week 12 was 3.4 mg twice daily. Missing data were imputed by last observation (or last rank) carried forward. At week 12, there was a statistically significant greater improvement in 6MWD in the treprostinil group compared with placebo (treatment effect, 23 meters [95% CI, 4 to 41]; Hodges-Lehmann rank estimator, p=0.013), a finding that was maintained in subgroup analyses. FDA reviewers noted that the robustness of the finding "depends heavily" on the method of analysis used; for example, giving all randomized individuals with missing data the lowest score yielded a statistically nonsignificant result (p=0.92). There was no statistical between-group difference in time to clinical worsening (defined as in the FREEDOM-C and FREEDOM-C2 trials), a secondary outcome, in any analysis. The most common adverse events in 233 individuals randomized to treprostinil were headache (69%), nausea (39%), diarrhea (37%), and jaw pain (25%). Sixteen randomized individuals died during the trial, 10 (4%) in the treprostinil group and 6 (5%) in the placebo group. Two deaths within the oral treprostinil group were considered possibly attributable to study drug. FDA reviewers did not note this in their review.

Expert opinion on the clinical utility of this drug differs. Although experts agree that oral administration of prostanoid will be a considerable advantage for individuals compared with continuous infused or inhaled administration, Feldman et al (2015) in Arizona raised concerns about inadequate dosing, interruptions to dosing, and switching to/from infused or inhaled prostanoids. In contrast, Skoro-Sajer et al (2014) in Austria did not share these concerns.

Ventavis (iloprost)

FDA approval of Ventavis (iloprost) was based in part on the results of a randomized, double-blind, multicenter placebo-controlled trial conducted in 203 adult individuals with PAH (WHO Group I); idiopathic (53%), associated with connective tissue disease including CREST and scleroderma (17%), or associated with anorexigen use (2%) or pulmonary hypertension related to chronic thromboembolic disease (WHO Group IV; 28%). The primary endpoint was a

composite endpoint at 12 weeks defined by 1) improvement in exercise capacity (6MWT) and 2) improvement by at least 1 NYHA class versus baseline; and no death or deterioration of pulmonary function. The response rate was 19% for the iloprost group compared to 4% for the placebo group. There was inadequate evidence of benefit in individuals with PH associated with chronic thromboembolic disease (WHO Group IV). The use of iloprost requires a specialized dispensing device. One limitation of this delivery system is that the drug may be lost in the device tubing.

Tracleer (bosentan)

The FDA approval of Tracleer (bosentan) was based in part on a randomized, placebo-controlled double-blind study of 213 individuals with PAH (idiopathic (70%) or associated with connective tissue disease (30%); WHO Group I. The primary endpoint was the degree of change in exercise capacity. At 16 weeks, a significant improvement was found in the 6MWT in the treatment group compared to the placebo group. Other measures of symptoms and functional status also improved in the treatment group, including a composite measure of "clinical worsening," which consisted of the outcomes of death, hospitalizations for PAH, discontinuation of therapy, or need for epoprostenol." In addition, the treatment group had a significant increase in cardiac index associated with reduction in the pulmonary artery pressure. A review article detailed 2 RCTs (n=310) that evaluated the effect of bosentan for the treatment of systemic sclerosis-associated digital ulcers. In both trials, there was significant improvement in hand function; however, no differences were seen in healing of established ulcers.

Letairis (ambrisentan)

FDA approval of Letairis (ambrisentan) was based on two 12-week randomized, double-blind, placebo-controlled multicenter studies of 393 individuals with PAH. ARIES-1 compared once-daily doses of 5 mg and 10 mg of ambrisentan to placebo, while ARIES-2 compared once-daily doses of 2.5 and 5 mg. Individuals were not taking any of the other agents discussed in this policy during the study. Sixty-four percent had idiopathic PAH, and 32% had PAH associated with connective tissue disease. Placebo-adjusted mean changes from baseline in the 6MWD were 51 meters in AIRES-1 and 59 meters in AIRES-2 (results for the higher dosages). For the two trials, clinical worsening was noted in 10% and 22% of the placebo individuals compared to 3% and 6% - all respectively, of those receiving ambrisentan. In 2010, Blalock published long-term outcomes in 12 of 14 individuals who were enrolled in the AIRES-1 study at a single institution; these individuals enrolled in an extension of the 12-week randomized period in

which all participants received ambrisentan. All of the 12 individuals remained on ambrisentan monotherapy during the first 2 years of follow-up. Two individuals developed worsening symptoms requiring add-on intravenous (IV) therapy toward the end of the second year; 2 others developed worsening symptoms after 2 years and began IV therapy. At last follow-up (3.5 to 5 years), 11 individuals remained alive; 3 were on ambrisentan monotherapy, 5 on combinations of oral therapies and 2 on ambrisentan plus an IV prostacyclin.

Opsumit (macitentan)

The pivotal SERAPHIN trial (2013) assessed the efficacy and safety of Opsumit (macitentan) to treat PAH. SERAPHIN was an event-driven, double-blind RCT in 742 individuals with PAH (55% idiopathic, 31% associated with connective tissue disease, 8% associated with congenital shunt). Both treated (excluding endothelin receptor antagonists) and untreated individuals were enrolled. Individuals were randomized to placebo or macitentan 3 mg or 10 mg once daily. The primary end point was a composite of morbidity (atrial septostomy, lung transplantation, or worsening of PAH) and all-cause mortality.

Median treatment duration was 2 years 2 months. Primary end point events occurred in 46% of the placebo group, 38% in the 3 mg macitentan group (hazard ratio [HR] vs. placebo, 0.70; 97.5% CI: 0.52 to 0.96; p=0.01), and 31% in the macitentan 10 mg group (HR vs. placebo, 0.55; 97.5% CI, 0.39 to 0.76; p<0.001). Results were consistent across multiple sensitivity analyses and prespecified subgroups (e.g., use or nonuse of concomitant PAH medication). The change from baseline in 6MWD at 6 months (a secondary outcome) was –9 meters in the placebo group, +7 meters in the 3 mg macitentan group (least squares mean difference vs. placebo, 17 meters; 97.5% CI: -3 to 36; p=0.01), and +13 meters in the 10 mg macitentan group (least squares mean difference vs. placebo, 22 meters; 97.5% CI: 3 to 41; p=0.008) from a baseline of 360 meters. Improvements in WHO functional class at month 6 in both macitentan groups were statistically significantly greater in both macitentan groups compared with placebo. Serious adverse events and discontinuations due to adverse events occurred with similar frequency in all 3 groups. Adverse events that occurred more commonly in macitentan-treated individuals included headache (13% vs. 9%), anemia (11% vs. 3%), and bronchitis (10% vs. 6%). Liver enzyme elevations, which are associated with bosentan (the parent drug of macitentan), occurred in approximately 4% of individuals in all 3 groups.

Revatio (sildenafil citrate)

FDA approval of Revatio (sildenafil citrate), also marketed as Viagra, was based in part on the results of a study that randomized 278 individuals with PAH (idiopathic [60%], connective tissue disease [40%] WHO Group 1) to receive either placebo or sildenafil (20, 40, or 80 mg), orally, 3 times daily for 12 weeks. The study is known as the SUPER-1 trial and the findings were published by Galie and colleagues in 2005. There was a significant improvement in primary endpoint, defined as the change in baseline to week 12 in the distance walked in 6 minutes (6MWD). Of the 222 individuals completing 1 year of treatment, the improvement in distance walked in 6 minutes was 51 meters. There was no significant difference among the 3 different doses of sildenafil given, and thus the recommended dose is 20 mg 3 times per day. At doses higher than the recommended dose, there was greater incidence of some adverse events including flushing, diarrhea, myalgia, and visual disturbances.

In 2011, Rubin et al. published findings from an open-label extension study for which all individuals who completed the initial trial were eligible (SUPER-2). In the extension study, all individuals titrated up to 80 mg sildenafil 3 times daily unless they could not tolerate this dose; there was no placebo group. A total of 259 of the 277 (93.5%) individuals in the SUPER-1 trial entered the extension study. Compared to their SUPER-1 baseline value, at 3 years, 127 of 277 (46%) of individuals had increased their 6MWD, 49 (18%) decreased their 6MWD, and 48 (17%) had missing data. A total of 81 individuals (29%) had at least a 60-meter improvement in the 6MWD compared to the SUPER-1 baseline, and another 22 (8%) had a 30- to 60-meter improvement. Three years from SUPER-1 baseline, 187 individuals were alive, 53 had died, and 37 were lost to follow-up. The Kaplan-Meier estimate of the survival rate, based on all randomized individuals, was 79%. The estimate of survival was 68% if all censored individuals were considered to have died. During the extension study, most adverse effects were mild or moderate in severity and were consistent with known side effects of sildenafil, e.g., headache, diarrhea, and dyspepsia. Serious adverse events were reported by 153 of 277 (55%) individuals. Serious events that were perceived to be treatment-related included grand mal seizure, hypotension, drug hypersensitivity, and gastroesophageal reflux disease (exact numbers of affected individuals were not reported). Thirty-nine individuals discontinued drug use due to adverse events. A major limitation of the extension study in terms of its ability to evaluate efficacy was that there was no comparison group of individuals who were not taking sildenafil.

Adcirca (tadalafil)

The pivotal trial on tadalafil (Adcirca), the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) study, was published by Galie et al. in 2009. This was a double-blind

multicenter study conducted in the United States, Canada, Europe, and Japan. It included 406 individuals who were at least 12 years-old and had symptomatic PAH (Group 1) that was idiopathic/heritable or related to anorexigen use, connective tissue disease, HIV infection or congenital systemic-to-pulmonary shunts. Randomization was stratified by type of PAH (idiopathic/heritable and anorexigen use versus other types), baseline bosentan use (53% were using bosentan), and baseline walking distance (less than 325 meters or at least 325 meters). Individuals were assigned to receive 16 weeks of treatment with placebo (n=82) or 1 of 4 doses of tadalafil: 2.5 mg (n=82), 10 mg (n=80), 20 mg (n=82), or 40 mg (n=79). A total of 331 (82%) individuals completed the 16-week study. Discontinuation rates were similar across all treatment groups, about 16% in each. The efficacy analysis was intention-to-treat and included 405 individuals (all those randomized minus 1 individual who did not receive study medication). The primary efficacy outcome was placebo-corrected change from baseline to 16 weeks in the 6MWD. Compared to placebo, only the individuals receiving 40 mg tadalafil significantly improved their 6MWD (i.e., the p value was less than the prespecified cutoff of 0.01). For the 392 participants who were assessed at 16 weeks, change in placebo-corrected 6MWD was as follows: 14 meters (95% CI: 6-33) for the 79 individuals in the 2.5-mg group, 20 meters (95% CI: 1-39) for the 78 individuals in the 10-mg group, 27 meters (95% CI: 11-44) for the 82 individuals in the 20-mg group, and 33 meters (95% CI: 15-50) in the 79 individuals in the 40-mg group. The statistical significance cutoff for secondary outcomes was 0.05. There were no statistically significant differences between any of the tadalafil groups and placebo in the proportion of individuals with improved WHO functional class and change in the Borg dyspnea scales. Time to clinical worsening, however, significantly improved in the tadalafil 40-mg group compared to placebo (p=0.041). Moreover, the 40-mg group had significantly greater improvement than placebo in 6 of the 8 quality-of-life domains in the Medical Outcomes Study 36-item short form (SF-36); the total quality-of-life score was not reported. Three deaths occurred during the 16-week study period; the study was not designed to evaluate differences in the mortality rate.

In 2012, Oudiz et al. reported results from the 52-week, multicenter PHIRST extension study, PHIRST-2. Of 364 eligible individuals (PHIRST completers [n=341] or those who discontinued due to clinical worsening [n=23]), 357 (98%) continued in PHIRST-2. Individuals were randomized in a double-blinded fashion to tadalafil 20 mg or 40 mg orally once daily. Sixty-three individuals received tadalafil 20 mg in both PHIRST and PHIRST-2, and 69 received tadalafil 40 mg in both studies; all other individuals (n=225) were randomized to receive tadalafil 40 mg in PHIRST-2. In the former groups, improvements in 6MWD achieved in PHIRST were maintained in PHIRST-2: In the group that received tadalafil 20 mg in both studies, 6MWD was 406±67 meters at the start and 415±80 meters at week 52 in PHIRST-2 (n=52). In the group that received tadalafil 40 mg in both studies, 6MWD was 413±81 meters at the start and 410±78 meters at week 52 in PHIRST-2 (n=59). In contrast, individuals who had received lower tadalafil

doses or placebo in PHIRST did not improve to similar levels after receiving 40 mg for 52 weeks. Headache was the most common adverse event, occurring in 14% and 16% of individuals receiving tadalafil 20 mg or 40 mg in both studies, respectively; these incidences were less than those observed in PHIRST (32% and 42%, respectively), suggesting that headache may wane over time.

Levitra (vardenafil)

Jing et al. published 2 studies from China evaluating Levitra (vardenafil); a case series in 2009 and an RCT in 2011. The case series included 45 individuals with PAH who were admitted for treatment at one of the participating study centers. Eligibility was limited to individuals with idiopathic PAH, advanced pulmonary vasculopathy associated with connective tissue disease and congenital heart disease or portopulmonary hypertension. Individuals were treated with oral vardenafil 5 mg daily for 1 month, after which time the dose was increased to 10 mg daily (5 mg twice a day) if tolerated. None of the individuals had received other PAH-active drugs in the previous 3 months, but individuals had been using vardenafil for a mean of 14 months before study entry. The mean baseline 6MWD was 409 meters (standard deviation [SD]: 103). All individuals were evaluated after 3 months of treatment at which time the 6MWD had increased a mean of 71 meters (SD: 78). The change in distance from baseline was statistically significant (p<0.001). All individuals were also evaluated after a mean of 14 months (SD: 3) of treatment. At this longer-term follow-up, the mean increase in 6MWD was 83 meters (SD: 92), which was significantly higher than baseline (p<0.001) but not higher than the distance walked at 3 months (p=0.36). Change in functional improvement was seen at both 3 months and 14 months. At baseline, 11 (24%) individuals were in WHO functional class II, 29 (64%) were in class III, and 5 (12%) were in class IV. At the end of the study, 5 (11%) were in functional class I, 31 (69%) in class II, 8 (18%) in class III, and 1 (2%) in class IV. No individuals died during the study; 2 individuals were admitted to the hospital for PAH-related symptoms after 6 and 11 months, respectively. The study was limited in that there was no comparison group, the sample size was small, and most individuals had previously received the study medication so they were more likely to continue to respond to it.

A double-blind RCT, published by Jing et al in 2011, was conducted at 8 centers in mainland China. The study randomized 66 individuals to receive 12 weeks of oral vardenafil monotherapy (n=44) compared to placebo (n=22). Individuals in the active treatment group received 5 mg vardenafil once daily for the first 4 weeks and then increased to the target dose of 5 mg twice daily, if tolerated. Two individuals dropped out before any follow-up data were recorded. Thirty-nine of the remaining 64 individuals (61%) had idiopathic PAH, 19 (30%) had connective tissue disease, and 6 (9%) had repaired right-to-left shunting. WHO functional class at baseline was

class II in 30 (47%) and class III in 34 (52%). Baseline 6MWD (the primary efficacy outcome) was a mean of 388 meters in the placebo group and 395 in the vardenafil group. A total of 59 individuals (89% of those randomized) completed the 12-week randomized phase. After 12 weeks, the median 6MWD increased by 59 meters in the vardenafil group and decreased by 10 meters in the placebo group. The mean placebo-corrected treatment effect was 69 meters (95% CI: 41 to 98 meters, p<0.001). During the 12-week follow-up period, 1 of 44 (2%) in the vardenafil group and 4 of 22 (18%) in the placebo group experienced clinical worsening; the difference between groups was statistically significant, p=0.044. This includes 2 individuals in the placebo group who died. Other clinical outcomes favored the treatment group. Ten of 44 (23%) individuals treated with vardenafil improved at least one WHO functional class, compared to only 1 of 22 (5%) of individuals in the placebo group. In addition, the mean Borg dyspnea scale improved at week 12 (mean decrease of 0.4 point) in the vardenafil group, whereas the dyspnea score worsened (increase of 1.8 points) in the placebo group; the authors did not report a between-group p value. Fifty-eight individuals completed a 12-week open-label extension of the study in which all individuals received vardenafil 5 mg twice a day. At the end of the extension phase, the mean improvement in the 6MWD in the group originally assigned to vardenafil was 69 meters. In addition, individuals who had been in the placebo group and then took vardenafil for 12 weeks had a mean increase of 59 meters in walk distance from week 12 (mean of 49 meters improvement from baseline). This remains the only published RCT evaluating vardenafil for PAH; no major study was conducted in the United States; a limitation is that the analysis was not intention-to-treat.

Adempas (riociguat)

The pivotal PATENT-1 trial (2013) assessed the efficacy and safety of Adempas (riociguat) to treat PAH. PATENT-1 was a double-blind RCT in 443 adults who had symptomatic PAH (61% idiopathic, 25% associated with connective tissue disease, 8% associated with congenital heart disease). Both treated (excluding phosphodiesterase type 5 inhibitors) and untreated individuals were enrolled. Individuals were randomized to placebo or riociguat titrated to 0.5 to 2.5 mg 3 times daily. (A second riociguat group capped at 1.5 mg three times daily [63 individuals] was excluded from efficacy analyses.) Dose was optimized during the first 8 weeks, and the optimized dose was continued for 4 additional weeks. The primary efficacy outcome was a mean change in 6MWD at week 12.

Approximately 90% of individuals in both groups completed the trial; 75% of completers in the riociguat group continued the maximum dose to week 12. Mean change in 6MWD was +30 meters in the riociguat group and –6 meters in the placebo group (least-squares mean difference, 36 meters; 95% CI: 20 to 52; p<0.001) from a baseline of 363 meters. Results were

consistent across multiple sensitivity analyses and predefined subgroups (e.g., use or nonuse of concomitant PAH medication). Improvements in PVR, N-terminal brain natriuretic peptide, WHO functional class, time to clinical worsening (defined as the first occurrence of death, transplantation, or other indicator of PAH worsening), and Borg dyspnea severity scale (an individual-reported outcome) also were statistically significantly greater in the riociguat group. Adverse events occurred with similar frequency across groups. Adverse events that occurred more commonly in riociguat-treated individuals included stomach upset (19% vs. 8%), hypotension (10% vs. 2%), and anemia (8% vs. 2%). Eight riociguat-treated individuals (3%) and 9 placebo-treated individuals (7%) discontinued study drug due to adverse events. Serious drug-related adverse events that led to riociguat discontinuation included increased hepatic enzyme levels, acute renal failure, and syncope.

Eighty-five percent of individuals in the riociguat group enrolled in an extension study. The mean increase in 6MWD in this group was 36±54 meters at week 12 of PATENT-1. At week 12 of the extension study (week 24 of treatment), there was continued improvement reported with a mean increase of 53±62 meters on preliminary analysis. At 1-year follow-up in 324 individuals (82%), mean increase in 6MWD from PATENT-1 baseline was 51±74 meters. WHO functional class improved in 33% of individuals, stabilized in 61%, and worsened in 6% compared with PATENT-1 baseline functional class.

Uptravi (selexipag)

A pivotal Phase 3, randomized, double-blind, placebo-controlled GRIPHON trial (2015) evaluated the efficacy and safety of Uptravi (selexipag) in 1156 individuals with pulmonary arterial hypertension. Individuals were eligible for enrollment if they were not receiving treatment for PAH or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary endpoint was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period. A primary endpoint event occurred in 397 individuals, with 27.0% in the selexipag group and 41.6% in the placebo group (hazard ratio 0.60; 99% CI 0.46 – 0.78; p<0.001). Disease progression and hospitalization accounted for 81.9% of the events. The most frequent adverse events leading to discontinuation in the selexipag group (14.3%) were headache (3.3%), diarrhea (2.3%), and nausea (1.7%). No serious adverse events were reported more frequently in the selexipag group than in the placebo group.

Simvastatin

In 2011, Kawut and colleagues published findings of a study evaluating simvastatin and aspirin, alone and together, for treating PAH. The study used a 2X2 factorial design and was double-blind and placebo-controlled. After enrolling the first 65 individuals, the Data Safety and Monitoring Board did an interim analysis. The analysis showed that it was highly unlikely that simvastatin would show improvement in the primary outcome, change in the 6MWD at 6 months, compared to aspirin or placebo and the study was terminated. No other RCTs were identified that studied any statin for treating PAH. This study represents insufficient evidence that simvastatin is an effective treatment for PAH.

Atorvastatin

In 2012, Zeng et al. published a 6-month, randomized, double-blind, placebo-controlled trial of 220 Chinese individuals with PAH (83%) or chronic thromboembolic pulmonary hypertension (CTEPH; 6%) in WHO functional class II or III. Individuals received atorvastatin 10 mg orally daily or matching placebo in addition to supportive care (diuretics, digoxin, and warfarin). After 6 months, the mean difference in 6MWD (atorvastatin – placebo) was 2.5 meters (95% CI: -33-[+]38). There was no statistically significant difference between treatment groups in the proportion of individuals who improved or deteriorated in WHO functional class, or in hemodynamic parameters (right atrial pressure, pulmonary artery pressure, cardiac index, PVR, or mixed venous oxygen saturation). There were 9 deaths in the atorvastatin group (8%) and 11 deaths in the placebo group (10%; $p=0.31$). The authors concluded, "Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months."

Section Summary

RCTs and several meta-analyses of RCTs have found that prostanoids, endothelin receptor antagonists, PDE5, and the soluble guanylate cyclase stimulator, riociguat, are all associated with small but statistically significant improvement in exercise capacity and hemodynamic parameters in individuals with PAH. Findings on mortality reduction are mixed; in general, the evidence base on the effect of approved treatments on mortality is limited by the small size and short duration of most trials. One terminated trial of simvastatin and 1 double-blind, placebo-controlled trial of atorvastatin indicated lack of efficacy of both drugs for treatment of PAH.

PAH Combination Therapy

RCTs have evaluated various combinations of medications for treating PAH. In addition, meta-analyses of RCTs have been published. The meta-analyses considered various combinations of medications; all of the individual trials included in the meta-analyses used medications from different classes. In addition, all trials used combination therapy as second-line treatment, i.e., individuals were already taking one medication when they entered the trial.

A meta-analysis published by Fox et al. in 2011 included 6 trials. The review's inclusion criteria included studies in which individuals on one active treatment were randomized to receive a second medication or placebo. In addition, studies needed to have at least 12 weeks of follow-up and to include clinical outcomes. A pooled analysis of data from 4 trials found a statistically significant increase in the 6MWD with combination therapy versus monotherapy (weighted mean difference [WMD]: 25.2 meters, 95% CI: 13.3 to 38.2). The clinical significance of this degree of difference between groups in the 6MWD is unclear. Other pooled analysis did not find significant differences between groups. A meta-analysis of data from 4 trials did not find a lower risk of mortality with combination versus monotherapy (risk ratio [RR]: 0.42, 95% CI: 0.08 to 2.26). In addition, a meta-analysis of 4 trials did not find a significant difference between groups in the rate of clinical worsening (composite variable including death, hospital admission, transplantation and treatment escalation) (RR: 0.42, 95% CI: 0.17 to 1.04).

Another meta-analysis was published by Bai and colleagues in 2011 and also included 6 trials. Inclusion criteria included RCTs on treatment of adults with PAH using combination therapy, follow-up of 8 weeks or more, and reporting of clinical outcomes. Five of 6 of the included articles were the same in both meta-analyses. The meta-analyses differed on the 6th article they included; one included Galie et al. (2009), and the other included Barst et al. 2011. However, these 2 studies reported on data from the same randomized trial. A pooled analysis of data from 5 trials found significantly greater improvement in the 6MWD with combination therapy compared to monotherapy (WMD: 22.2, 95% CI: 13.6 to 30.9). In addition, a pooled analysis of data from 5 trials found a significantly lower rate of clinical worsening with combination compared to monotherapy (RR: 0.48, 95% CI: 0.26 to 0.91). Clinical worsening referred to death, hospitalization, symptomatic deterioration, lack of improvement, interatrial fistulization, transplantation, or treatment escalation. A pooled analysis of data from 5 trials did not find a significant difference between groups in the risk of mortality (RR: 0.44; 95% CI: 0.04 to 4.65).

The 2 meta-analyses both found that combination therapy resulted in significantly greater improvement in the 6MWD compared to monotherapy and both found no difference between groups in mortality. The Bai et al. meta-analysis, but not the Fox et al. meta-analysis, found a

significantly lower rate of clinical worsening in the combination therapy group; clinical worsening was defined somewhat differently in the 2 meta-analyses.

The 2013 Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review previously described above included 5 RCTs of combination therapies. As in the Fox et al. and Bai et al. meta-analyses, treatments from different classes were combined in the meta-analyses of the AHRQ review, and all treatment combinations were add-on therapies. Evidence was insufficient to form any conclusion about combination therapy in comparison to continuation of monotherapy for the outcomes of mortality or hospitalization. Low strength of evidence supported an association between greater improvement in the 6MWD with combination therapy compared to continued monotherapy (mean difference in distance walked 23.9 meters [95% CI: 8.0-39.9]). Because the magnitude of the treatment effect is less than the commonly accepted MID of 33 meters, the clinical significance of this finding is uncertain.

A 2012 meta-analysis by Zhu et al. incorporated results from 5 of the 6 RCTs discussed below; the EARLY trial evaluating sildenafil add-on therapy to bosentan in mildly symptomatic individuals was excluded, and 1 small RCT (N=39) of sildenafil added to bosentan therapy was included. In 3 trials, inhaled prostanoid was added to bosentan or sildenafil, and in 3 trials, a PDE5 inhibitor was added to bosentan or epoprostenol. A total of 735 individuals were evaluated for the 6MWD outcome. The pooled treatment effect (weighted mean difference, combination - monotherapy) was 21.6 meters (95% CI: 13.3-29.9), less than the MID described above. For the outcome of clinical worsening (death, hospitalization, symptomatic deterioration, lack of improvement or the need for treatment escalation [such as additional drugs], the development of an interatrial fistula, or lung transplantation), 729 individuals were evaluated. The incidence of clinical worsening was lower in the combination therapy group than in the monotherapy group (risk ratio: 0.43 [95% CI: 0.26-0.72]). Results were primarily driven by 2 large trials which together comprised 68% of the individual sample.

The key RCTs evaluating combination treatment for PAH are described below; studies are organized according to the classes of medications that were combined.

Prostacyclin Analogues and Endothelin Receptor Antagonists

Three randomized trials evaluated the combination of inhaled iloprost and bosentan on clinical outcomes. In 2006, McLaughlin et al. conducted a randomized double-blind trial of adding iloprost or placebo to bosentan monotherapy in 67 individuals with PAH (idiopathic, 55%, associated PAH, 45%). After 12 weeks, treatment with iloprost resulted in a placebo-adjusted 6MWD improvement of 26 meters (p=0.05). Functional class, hemodynamic parameters (e.g.,

pulmonary arterial pressure, -6 mm Hg vs. +3 mm Hg in the treatment and placebo groups, respectively), and time to clinical worsening (p=0.02) were all improved at 12 weeks in the treatment group compared with the placebo group. Hoeper et al. reported results from a small (n=40), 12-week, nonblinded RCT evaluating the addition of iloprost to bosentan monotherapy in individuals with idiopathic PAH (IPAH, WHO Group 1). The study was terminated early because there appeared to be no benefit from the combined therapy: change was -10 meters on 6MWD for the combination group and no difference in functional status, VO2 max (maximum oxygen consumption during exercise), and time to clinical worsening. The study noted that these results may have been skewed by 3 individuals in the iloprost group who presented with severe clinical worsening. In 2017, Han et al. published results for an open-label RCT evaluating the combination of bosentan and iloprost in 27 treatment-naïve individuals with PAH by comparing to bosentan and iloprost monotherapy. The primary endpoint, 6MWD, was evaluated at 6 weeks and 3 months after initiation of treatment compared with baseline values. The 6MWD significantly improved with combination therapy (95.6 meters and 133.75 meters) compared to both bosentan (1.3 meters and 0.86 meters) and iloprost (-0.67 meters and 10.2 meters) monotherapy groups at week 6 (p=0.001) and after 3 months (p<0.001). However, due to the small sample size and open-label study design, the study noted that additional studies with large samples and placebo controls were required to further assess the treatment efficacy and tolerability of combination therapy for PAH.

In 2010, McLaughlin et al. evaluated the addition of inhaled treprostinil to oral therapy in a double-blind RCT with 235 individuals with PAH. Individuals had been on a stable dose of bosentan (n=165) or sildenafil (n=70) for at least 3 months. They were randomized to receive inhaled treprostinil sodium (up to 54 mug or placebo 4 times daily as add-on therapy. A total of 212 (90%) individuals completed the study; analysis was intention to treat. The primary efficacy outcome was change in 6MWD over 12 weeks. Mean baseline 6MWD was 346 meters in the inhaled treprostinil group and 351 in the placebo group. After 12 weeks, the median change in peak 6MWD (10-60 minutes after nebulizer use) was 21.6 meters in the treprostinil group and 3.0 meters in the placebo group. The median between-group difference was 20 meters (95% CI: 8.0 to 32.8; p=0.004). When the analysis was limited to the individuals taking bosentan at baseline, the median difference in change in 6MWD over 12 weeks was 25 meters (p=0.002). There were no differences between groups in the secondary end points rate of clinical worsening, Borg dyspnea scores, change in NYHA functional classifications or PAH signs and symptoms. For example, 4 of 115 (3%) individuals in the treatment group and 6 of 120 (5%) in the placebo group experienced clinical worsening during the 12-week follow-up period. Another secondary outcome was quality of life, measured by the Minnesota Living with Heart Failure (MLWHF) questionnaire; the potential range of the total score is 0 to 105, with a higher score indicating a worse quality of life. There was a median difference between groups of -4 points in

the total score of the MLWHF; this difference was statistically significant, favoring the inhaled treprostinil group (p=0.027). Differences between groups in the 6MWD and quality-of-life measure may not be clinically significant. Following the 12-week double-blind study, individuals had the option of enrolling in an open-label extension study in which all individuals received inhaled treprostinil. A total of 206 of 235 (88%) individuals participated in the extension study. Their mean (SD) 6MWD at baseline was 349 meters. The median change in 6MWD was 31 meters (p<0.001, n=152) at 12 months and 18 meters (p=0.013, n=118) at 24 months. A limitation of this analysis was that there was no comparison with individuals who were not taking inhaled treprostinil.

The 2004 Bosentan Randomized trial of Endothelin Antagonist Therapy for PAH (BREATH-2) trial compared epoprostenol alone with the combination of epoprostenol plus bosentan. The trial was multicenter, double-blind, and placebo-controlled. It included 33 individuals with PAH who were scheduled to begin treatment with epoprostenol. After 2 days of epoprostenol therapy, individuals were randomized to add bosentan (n=22) or placebo (n=11). The double-blind treatment duration was 16 weeks, and the primary efficacy outcome was change in total pulmonary resistance. Five (15%) of 33 individuals did not complete the study. At 16 weeks, mean change in total pulmonary resistance did not differ significantly between groups (-36.3 dyns^{-1}cm^5 ± 4.3% in the combination treatment group vs -22.6 ± 4.3% in the epoprostenol plus placebo group, p=0.08). Secondary outcomes also did not differ significantly between groups. For example, the 6MWD increased a median of 68 meters in the combination treatment group and 74 meters in the epoprostenol plus placebo group. Moreover, the modified New York Heart Association functional class improved for 59% of individuals in the combination treatment group and 5 individuals in the epoprostenol plus placebo group (p=*NS*).

Prostacyclin Analogs and Phosphodiesterase Inhibitors

In the 2010 McLaughlin et al. study, previously discussed, individuals on monotherapy were randomized to receive added inhaled treprostinil or placebo; 70 individuals were taking sildenafil at baseline. In this subgroup, the median placebo-corrected change in 6MWD at 12 weeks, the primary outcome, was 9 meters; the difference between groups was not statistically significant. As previously noted, the groups did not differ significantly on secondary efficacy outcomes other than quality of life.

Simonneau et al. assessed the effect of adding oral sildenafil to long-term intravenous epoprostenol (n=267) with PAH in a 2008 RCT. After 16 weeks, the adjusted mean change in the 6MWD was 29.8 meters for the sildenafil group and 1.0 meter for the placebo group, a treatment difference of 28.8 meters (13.9 to 43.8 meters). In individuals with IPAH, the difference

between groups was 33.9 meters in favor of the sildenafil group (p value and 95% CI not reported). Sildenafil also had a beneficial effect on hemodynamic measurements and health-related quality of life.

Prostacyclin Analogs Plus Endothelin Receptor Antagonists and/or Phosphodiesterase Inhibitors

The 2 pivotal trials of oral treprostinil in individuals on background PAH therapy, FREEDOM-C and FREEDOM-C2, were similar in design with the exception of the starting dose of oral treprostinil. In FREEDOM-C, starting dose was 1 mg twice daily, which may have reduced tolerability and contributed to a high dropout rate. Based on this observation, starting dose in FREEDOM-C2 was decreased to 0.25 mg twice daily.

FREEDOM-C (N=350) and FREEDOM-C2 (N=310) were 16-week, multicenter, double-blind, placebo-controlled RCTs. Eligible individuals had symptomatic PAH; were receiving stable doses of approved PDE5 inhibitors and/or endothelin receptor antagonists and could walk a minimum of 100 meters in 6 minutes at baseline (minimum 6MWD). Individuals were randomized 1:1 to receive add-on oral treprostinil, administered twice daily at the specified starting dose (1 mg in FREEDOM-C and 0.25 mg in FREEDOM-C2) and increased as tolerated every 3 days, or matching placebo. The primary end point was change from baseline 6MWD at 16 weeks; trials were powered to detect a 35-meter between-group difference in 6MWD at 16 weeks. Secondary end points included time to clinical worsening (e.g., death, transplantation, atrial septostomy, hospitalization related to PAH, or initiation of a new PAH therapy).

Mean individual age was 51 years (range, 15-76). PAH etiologies were idiopathic or heritable (66%), collagen vascular disease (29%), congenital heart defect (4%), and HIV (1%). Functional status was predominantly WHO class II (23%) and class III (74%). Mean baseline 6MWD was 345 meters in FREEDOM-C and 330 meters in FREEDOM-C2. In FREEDOM-C, 39 individuals (22%) receiving oral treprostinil and 24 individuals (14%) receiving placebo discontinued study drug; discontinuations due to adverse events occurred in 25 individuals and 8 individuals, respectively. No individual in the oral treprostinil group who was subsequently started at a lower dose discontinued treatment due to adverse events. Median treprostinil dose at week 16 was 3 mg twice daily. In FREEDOM-C2, 25 individuals (16%) receiving oral treprostinil and 15 individuals (10%) receiving placebo discontinued study drug; discontinuations due to adverse events occurred in 18 individuals and 5 individuals, respectively. Mean maximum dose of treprostinil at week 16 was 3.1 mg twice daily. In both trials, missing data were imputed by last observation (or last rank) carried forward. Neither trial met the primary efficacy end point. Median between-group differences in change from baseline 6MWD at week 16 (oral treprostinil – placebo) were

11 meters and 10 meters in FREEDOM-C and FREEDOM-C2, respectively. No statistically significant between-group differences were observed in subgroup analyses or for any secondary outcome, including time to clinical worsening. In both trials, the most common prostacyclin-related adverse events leading to treprostinil discontinuation were headache (7%), nausea (5%), vomiting (3%), and diarrhea (3%). Ten individuals in FREEDOM-C2 died during the trial, 6 (4%) in the oral treprostinil group and 4 (3%) in the placebo group. Although 3 deaths within the oral treprostinil group were considered possibly attributable to study drug, FDA reviewers considered the deaths due to underlying disease.

FDA review documents and the prescribing information for oral treprostinil describe an open-label extension study for individuals who participated in any of the FREEDOM trials, remained on study drug, and completed all scheduled visits (N=824). Individuals from treprostinil groups continued dose escalation as tolerated from their final dose during the trial; individuals from placebo group initiated treprostinil at 0.25 mg twice daily. PAH etiologies were idiopathic or heritable (70%), collagen vascular disease (24%), congenital heart defect (5%), and HIV (1%). Functional status was predominantly WHO class II (33%) and class III (64%). Mean oral treprostinil dose increased from 3.7 mg twice daily at 6 months to 5.3 mg twice daily at 3 years. Mean and maximal exposure to treprostinil was 2 years and 6 years, respectively. At 1 year, mean change from baseline 6MWD was 26 meters in all individuals (monotherapy and add-on therapy). Twenty-three percent of individuals discontinued treatment due to adverse events, most commonly PH, headache, and nausea. One-, 2-, and 3-year overall survival estimates (92%, 87%, 82%, respectively) are difficult to interpret in the absence of a control group.

Endothelin-Receptor Antagonists and Phosphodiesterase Inhibitors

An RCT by Galie et al. evaluated bosentan in mildly symptomatic individuals; the impact of combination therapy with bosentan and sildenafil was assessed in a subgroup of individuals as a secondary objective. The analysis assessed the effect of bosentan versus placebo and the effect of bosentan combined with sildenafil versus placebo. There was no direct comparison between the bosentan and combination treatment groups. The sample size of this study was small. In addition, individuals with idiopathic PAH (IPAH) and those with PAH secondary to HIV, congenital heart disease, and connective tissue disease were included. It is not clear if the same results would be expected for only those with IPAH.

In a 2015 prospective, double-blind study by McLaughlin et al., 334 symptomatic PAH individuals received stable sildenafil plus bosentan or placebo. The composite primary endpoint was the time to first morbidity/mortality event, defined as all-cause death, hospitalization for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH

worsening. The primary endpoint event occurred in 51.4% of individuals randomized to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58 – 1.19; p=0.2508). The secondary endpoint of change in 6MWD had a mean between-treatment difference at 16 weeks of +21.8 meters (95% CI +5.9 – 37.8 m; p=0.106. Overall, the study showed that combination therapy of bosentan plus sildenafil was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event, but the authors did note that the complexities of this composite endpoint and extent of missing information due to individuals discontinuing the study prematurely are potential contributing factors for this insignificant result. The Galie et al. study on tadalafil, discussed previously, included a predefined subgroup analysis comparing treatment effectiveness in individuals who added tadalafil to baseline bosentan treatment and those taking only tadalafil. These findings were reported by Barst and colleagues in 2011. The analysis focused on the groups assigned to 40 mg tadalafil and placebo. At 16 weeks, there was statistically significant improvement in the 6MWD among individuals taking tadalafil monotherapy but not in the group taking combination therapy. The placebo-corrected 6MWD was 44 m (95% CI: 20 to 69) in the tadalafil-only group and 23 m (95% CI: -2 to 48) in individuals taking the combination of tadalafil and bosentan.

Another double-blind RCT study in 2015 by Galie et al. evaluated 500 individuals with PAH who had not previously received treatment to receive initial combination therapy with ambrisentan plus tadalafil, ambrisentan plus placebo, or tadalafil plus placebo. The primary endpoint was the time to the first event of clinical failure, defined as the first occurrence of a composite of death, hospitalization for worsening PAH, disease progression, or unsatisfactory long-term clinical response. The endpoint event occurred in 18%, 34%, and 28% of the subjects in these groups, with 31% in the pooled-monotherapy group (hazard ratio 0.50, 95% CI 0.35 – 0.72; p<0.001 for the combination therapy group compared with the pooled-monotherapy group. The study noted that the treatment effect was mainly driven by a lower rate of hospitalization for PAH in the combination therapy group. However, there was actually no significant difference in WHO functional class among study groups at Week 24, despite improvements in other factors.

Tyrosine Kinase Inhibitors and Any of Three Major Classes of Medications

In 2010, Ghofrani and colleagues published findings of a multisite double-blind Phase II randomized trial evaluating imatinib as an add-on treatment in individuals with PAH; the study was conducted at sites in the United States and Europe. Fifty-nine individuals age 18 and older were enrolled; all had been on stable PAH medications for more than 3 months before enrollment but remained symptomatic. Individuals were taking a prostacyclin analog, endothelin-receptor antagonist, PDE5, or combinations of these medications. Individuals in WHO functional class II-IV were eligible. Participants were randomized to receive 6 months of

treatment with imatinib or placebo. Thirty-eight of 59 (64%) completed the study; 2 individuals in each group died during the follow-up period. Analysis was intention to treat. In the treatment group, an initial dose of 200 mg oral imatinib was given for 2 weeks; if tolerated, the dose was increased to 400 mg. The primary efficacy outcome was change in the 6MWD. At 6 months, mean change in the 6MWD was an increase in 22 meters in the imatinib group and a decrease of 1 meter in the placebo group; this difference was not statistically significant, p=0.21. Findings were similar regardless of the method used to impute missing data.

In 2013, Hoeper et al. published a 6-month, international, randomized, placebo-controlled trial of add-on imatinib 400 mg orally once daily (reduced to 200 mg if not tolerated) in 202 individuals with advanced PAH who were receiving at least 2 PAH therapies. Most individuals (approximately 40% in each group) were receiving triple therapy with an endothelin-receptor antagonist, a PDE5 inhibitor, and a prostanoid. The trial was completed by 67% of imatinib-treated individuals and 82% of placebo-treated individuals; most discontinuations were due to adverse events in both groups (26% in the atorvastatin group, 7% in the placebo group). The mean between-group difference in 6MWD (imatinib-placebo) was 32 meters (95% CI: 12-52), a finding that was robust to multiple modes of imputing missing data. Mortality, functional class, and time to clinical worsening (death, overnight hospitalization for worsening PAH, worsening of WHO functional class by at least 1 level, or a 15% or greater decrease from baseline 6MWD) did not differ between treatment groups. In a subset of 150 individuals (approximately 70 imatinib-treated and 80 placebo-treated individuals), statistically significant improvements in hemodynamic parameters (PVR, cardiac output, mean pulmonary artery pressure, and right atrial pressure) were observed with imatinib compared to placebo. Of 150 individuals who completed the trial, 144 (66 imatinib-treated and 78 placebo-treated individuals) entered an extension study of open-label imatinib. Among individuals who received 48 weeks of imatinib therapy, mean increase in 6MWD from baseline was 45±46 meters; among placebo-treated individuals who received imatinib in the extension study (24 weeks of imatinib therapy), mean increase in 6MWD from baseline was 19±72 meters (p=0.98). Serious adverse events occurred in 44% of the imatinib group and 30% of the placebo group; the most common serious adverse events in the imatinib group trial were anemia, dyspnea, peripheral edema, and presyncope. Subdural hematoma occurred in 8 individuals co-treated with imatinib and anticoagulation and in no individuals treated with placebo. Given the risk-benefit profile observed in the trial, the authors conclude that "the off-label use of imatinib for this indication is strongly discouraged."

Section Summary

Meta-analyses of trials on combination therapy have included studies that use medications from different classes and evaluate the addition of a second medication in individuals already taking

medication. 2 meta-analyses, which included data from the same 6 trials, have found small, statistically significant improvement in the 6MWD and have not found a significant benefit of combination therapy on mortality. Meta-analyses had mixed findings on the impact of combination therapy on clinical worsening, depending on how this variable was defined by the authors of the meta-analysis. There are few RCTs on any particular combination of therapies and findings of these studies are mixed. The evidence is sufficient to determine that combinations of classes of medications improve exercise capacity more than a single medication, although the impact on other outcome measures is not conclusive. Randomized trials of imatinib add-on therapy indicated no additional improvement with imatinib in most outcomes measured, and potential harm (subdural hematoma).

CTEPH Monotherapy

Riociguat

The pivotal CHEST-1 trial (2013) assessed the efficacy and safety of riociguat to treat CTEPH. CHEST-1 was a double-blind RCT in 261 adults who had inoperable CTEPH (72%) or persistent PH after pulmonary endarterectomy (28%). Individuals receiving PAH medications were excluded. Individuals were randomized to placebo or riociguat titrated to 0.5 to 2.5 mg 3 times daily. Dose was optimized during the first 8 weeks, and the optimized dose was continued for 8 additional weeks. The primary efficacy outcome was change in 6MWD at 16 weeks.

Approximately 93% of individuals in each group completed the trial; 77% of completers in the riociguat group continued the maximum dose to week 16. Mean change in 6MWD was +39 meters in the riociguat group, and –6 meters in the placebo group (least-squares mean difference, 46 meters; 95% CI: 25 to 67; $p<0.001$) from a baseline of 347 meters. Results were consistent across multiple sensitivity analyses and predefined subgroups (e.g., baseline WHO functional class). Improvements in PVR, N-terminal brain natriuretic peptide, and WHO functional class also were statistically significantly greater in the riociguat group. Adverse events occurred in 92% of the riociguat group and 86% of the placebo group. Adverse events that occurred more commonly in the riociguat group included headache (25% vs. 14%), dizziness (23% vs. 12%), stomach upset (18% vs. 8%), vomiting (10% vs. 3%), diarrhea (10% vs. 5%), and hypotension (9% vs. 3%). The most common serious adverse events were right ventricular failure (3% in each group), syncope (2% riociguat vs 3% placebo), and hemoptysis (2% riociguat). One individual died due to acute renal failure attributed to riociguat.

Seventy-five percent of individuals in the riociguat group enrolled in an extension study; mean increase in 6MWDin this group was 51±62 meters at week 16 of CHEST-1 and 63±64 meters in preliminary analysis at week 12 of the extension study (week 28 of treatment).

Additional data on secondary outcomes from CHEST-1 were published by Kim et al in 2017 Study findings generally favored the riociguat group. At week 16, compared with baseline, PVR significantly decreased in the riociguat group (-29%) compared with the placebo group (+3%). There were also significantly improved outcomes in the riociguat group vs placebo for other hemodynamic outcomes (e.g., systemic vascular resistance, mean pulmonary artery pressure, diastolic pulmonary artery pressure, cardiac output, mixed venous oxygen saturation, mean arterial pressure, diastolic pressure gradient; $p<0.001$ for each).

CTEPH Perioperative Therapy

For individuals with CTEPH who are eligible for pulmonary endarterectomy, preoperative elevation of PVR (>1100 Wood units) can increase operative mortality rates to 6% to 10%. Several studies have investigated the use of PAH-specific treatments to reduce elevated PVR preoperatively in individuals with CTEPH who are candidates for pulmonary endarterectomy.

Bosentan

In 2010, Reesink et al. reported results of a single-blind RCT in 26 individuals with CTEPH who were eligible for pulmonary endarterectomy. Mean baseline total pulmonary resistance was approximately 1000 Wood units. Fourteen individuals received bosentan for 16 weeks before surgery; 1 individual developed liver enzyme elevations to 6 times the upper limit of normal and was excluded from efficacy analyses. Eleven individuals in the bosentan group and 10 individuals in the no-bosentan group underwent pulmonary endarterectomy. Mortality rates within 30 days after surgery were 9% and 30%, respectively.

Epoprostenol

Nagaya et al. (2003) retrospectively examined the effect of preoperative intravenous prostacyclin analog (epoprostenol). Of 33 consecutive individuals with CTEPH who underwent pulmonary endarterectomy, 12 individuals with preoperative PVR greater than 1200 Wood units received preoperative epoprostenol for a mean of 6±2 weeks. Statistically significant reductions in PVR before surgery and further reductions after surgery led to a statistically nonsignificant difference

between groups 1 month after surgery (mean PVR approximately 300 Wood units in both groups). The only individual who died within 30 days after surgery was in the epoprostenol group for an overall mortality rate of 3.0% (8.3% mortality rate in the epoprostenol group; 0% in the comparator group).

In a similar study, Bresser et al. (2004) retrospectively reviewed 9 individuals who had received IV epoprostenol for a median of 4 months (range, 2-26) before pulmonary endarterectomy. Median baseline total pulmonary resistance was 1432 Wood units, and median baseline PVR was 1031 Wood units. (Baseline PVR could not be calculated in 1 individual.) Preoperatively, median total PVR decreased to 1000 Wood units, and median PVR decreased to 760 Wood units. Median total pulmonary resistance on postoperative day 1 or 2 was 350 Wood units.

Iloprost

In 2003, Kramm et al. reported on the effect of inhaled iloprost in the perioperative period. Ten individuals with mean PVR of 972 Woods units received inhaled iloprost at 3 time points: immediately before surgery, upon admission to the intensive care unit after surgery, and at 12 or more hours after surgery. Preoperative inhalation did not affect PVR. After surgery, PVR decreased 10% and 22% after each postoperative dose compared with placebo (saline) inhalation at the same time points; however, all postoperative measurements (pre- and posttreatment) were less than 360 Wood units. One individual died 17 days after surgery due to persistent pulmonary hypertension (10% mortality rate).

Riociguat

There are no trials evaluating riociguat for preoperative therapy. Because of the different mechanism of action for the different drugs, results from the studies previously described cannot be extrapolated to riociguat.

Sotatercept

Winrevair (sotatercept-csrk) is an activin signaling inhibitor. It is designed to work by enhancing the balance between pro- and anti-proliferative signaling pathways to modulate vascular proliferation. The approval is supported by results from the Phase 3 STELLAR study, which compared Winrevair to placebo as an add-on to standard-of-care background therapies in a total of 323 adults with PAH (WHO Group 1 FC II or III). Compared with individuals who received

placebo, individuals who received Winrevair experienced a median increase of 41 meters in 6-minute walk distance at 24 weeks, and had an 84% lower risk of all-cause death and nonfatal clinical worsening of PAH. In addition, results from the STELLAR study showed that Winrevair was generally well tolerated, with the most common adverse reactions being headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, and erythema. The prescribing information for Winrevair includes warnings and precautions regarding increased hemoglobin (Hb) levels, thrombocytopenia, severe bleeding, embryo-fetal toxicity, and impaired fertility.

Summary of Evidence

There is evidence from multiple randomized controlled trials (RCTs) and meta-analyses of RCTs that monotherapy using prostanoids, endothelin-receptor antagonists, phosphodiesterase type 5 (PDE5) inhibitors, or the soluble guanylate cyclase stimulator, riociguat, improves health outcomes in individuals with World Health Organization (WHO) Group 1 PAH. Thus, US Food and Drug Administration (FDA)–approved medications in these classes may be considered medically necessary for the treatment of individuals with pulmonary arterial hypertension (PAH). Evidence on the comparative efficacy of these individual agents is lacking; therefore it is not possible to determine which one is preferable as the first-line choice for treatment. There is insufficient evidence that simvastatin, atorvastatin, or imatinib are effective for treating individuals with PAH, and these medications do not have FDA-approved PAH indications. Thus, simvastatin, atorvastatin, and imatinib are considered investigational.

There is evidence from trials on combination therapy and meta-analyses of these trials that combination therapy as second-line treatment using medications from different classes results in improvement in exercise capacity; evidence on mortality and clinical worsening is inconclusive. Additionally, evidence is lacking on which particular combination of medications is optimal. Clinical input in 2011 uniformly thought that at least some therapy combinations were beneficial. Therefore, combination therapy as second-line treatment may be considered medically necessary when certain conditions are met. Additional trials on combination treatment are underway, including at least 1 evaluating combination therapy as first-line treatment. Riociguat is contraindicated with PDE5 inhibitors.

There is evidence from 1 RCT that riociguat improves health outcomes in individuals with chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4 PH) who are ineligible for pulmonary endarterectomy or have persistent pulmonary hypertension (PH) after pulmonary endarterectomy. Riociguat is therefore considered medically necessary in these individual groups. Riociguat has not been studied to reduce elevated preoperative pulmonary vascular resistance in individuals eligible for pulmonary endarterectomy. There is insufficient evidence for

the use of any PAH-specific medication in this setting; clinical input did not support the medical necessity of riociguat or PAH-specific medications for this use. Due to lack of evidence and lack of support from clinical vetting, PAH-specific medications and riociguat are considered investigational for this indication.

Practice Guidelines and Position Statements

Pulmonary Arterial Hypertension

In 2019, the American College of Chest Physicians (ACCP) updated their guidelines on pharmacologic therapy for PAH in adults. Relevant new recommendations include:

- For individuals with PAH who are treatment naive with World Health Organization (WHO) functional class (FC) II or class III symptoms, "an initial combination therapy with ambrisentan and tadalafil to improve 6MWD [6-minute walk distance]" is suggested (a weak recommendation with moderate quality evidence).

- "For stable or symptomatic PAH individuals on background therapy with ambrisentan," a weak recommendation with low-quality evidence is made for the addition of tadalafil to improve 6MWD.

- To delay time to clinical worsening in treatment naive PAH individuals with WHO FC II symptoms, the guidelines recommend bosentan, macitentan, or riociguat (all ungraded consensus-based statements).

- To improve 6MWD for treatment-naive individuals with WHO FC III symptoms, the guidelines recommend bosentan(strong recommendation, moderate quality evidence), ambrisentan (strong recommendation, low quality evidence),sildenafil (strong recommendation, low-quality evidence), tadalafil (ungraded consensus-based statement), or riociguat (ungraded consensus-based statement).

- To delay time to clinical worsening in PAH individuals who are treatment naive with WHO FC III symptoms, the guidelines recommend macitentan, tadalafil, or riociguat (all ungraded consensus-based statements).

- For individuals with PAH who are treatment-naive, have WHO functional class II or class III symptoms, and "who are not candidates for, or who have failed, CCB [calcium channel blocker] therapy, " monotherapy with an "approved endothelin receptor antagonist (E RA),

phosphodiesterase-5 (PDE-5) inhibitor (PDE5I), or ... riociguat" is advised for individuals who are "unwilling or unable to tolerate combination therapy" with ambrisentan and tadalafil.

- For individuals with PAH in WHO functional class III "who have evidence of rapid progression of their disease…" initial treatment with a parenteral prostanoid "should be considered". For individuals with a "poor clinical prognosis despite treatment with one or two classes of oral agents," consideration of the "addition of a parenteral or inhaled prostanoid" is recommended.

- For individuals with PAH who are treatment-naive and have WHO functional class IV symptoms, initial therapy with a parenteral prostanoid agent" is recommended. If individuals "are unable or do not desire to manage parenteral prostanoid therapy, "combination treatment with "an inhaled prostanoid" and "an oral PDE5I and an E RA" is recommended.

In 2013, the ACCP and American Heart Association released a joint policy statement, The Choosing Wisely Top Five List in Adult Pulmonary Medicine. The list includes a recommendation to not routinely offer advanced vasoactive agents approved only for the management of PAH to individuals with disease resulting from left heart disease or hypoxemic lung disease (group II or III PH).

Chronic Thromboembolic PH

The 2009 ACCF/AHA Expert Consensus Document on Pulmonary Hypertension recommended pulmonary endarterectomy for eligible individuals with CTEPH. The panel noted that pharmacotherapy with PAH-specific medications may benefit CTEPH individuals who are ineligible for pulmonary endarterectomy due to significant distal disease or comorbidity; individuals who have persistent pulmonary hypertension due to residual distal disease after pulmonary endarterectomy; and individuals eligible for pulmonary endarterectomy who are considered high-risk due to poor functional status or hemodynamics and may benefit from presurgical treatment with intravenous epoprostenol. The panel recommended that PAH-specific medications be used for CTEPH individuals only when "appropriate secondary preventive measures, including anticoagulation, have been instituted" and "the individual's symptoms suggest that PAH-specific therapy may yield clinical benefit."

An American Heart Association (AHA) scientific statement (2011) makes the following recommendations for medical therapy and pulmonary endarterectomy in individuals with CTEPH:

- Individuals with CTEPH should be promptly evaluated for pulmonary endarterectomy, even with mild symptoms.

- Individuals with CTEPH "should receive indefinite therapeutic anticoagulation in the absence of contraindications."

- "PAH (WHO Group I)-specific medical therapy may be considered for individuals with CTEPH who are not surgical candidates…or who have residual pulmonary hypertension after operation not amenable to repeat pulmonary endarterectomy…."

- "PAH (WHO Group I)-specific medical therapy should not be used in lieu of pulmonary endarterectomy or delay evaluation for pulmonary endarterectomy for individuals with…CTEPH who are or may be surgical candidates."

Medicare National Coverage

There is no national coverage determination.

Regulatory Status

Table 1 summarizes the advanced therapies for treatment of PAH (WHO Group 1) and their regulatory status:

Table 1: Advanced Treatments of PAH and Their Regulatory Status

Drug Brand Name Manufacturer FDA Approval Date	Route(s) of Administration Dose range	FDA Approved Indications
Prostacyclin Analogues		
epoprostenol sodium (FLOLAN) GlaxoSmithKline FDA approved 1995	Continuous intravenous IV infusion via central venous catheter using an ambulatory infusion pump 1 to 20 ng/kg/min	Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity. Studies establishing effectiveness included predominantly individuals with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable

Drug Brand Name Manufacturer FDA Approval Date	Route(s) of Administration Dose range	FDA Approved Indications
		PAH or PAH associated with connective tissue diseases.
epoprostenol sodium (Veletri) Actelion Pharmaceuticals US, Inc. FDA approved 1995	Continuous intravenous IV infusion via central venous catheter using an ambulatory infusion pump 1 to 20 ng/kg/min	Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity. Studies establishing effectiveness included predominantly individuals with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
treprostinil sodium (REMODULIN) United Therapeutics Corp. FDA approved 2002	Continuous subcutaneous (SC) infusion IV infusion (if SC infusion not tolerated) 0.625 to 1.25 ng/kg/min	Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included individuals with NYHA Functional Class II-IV symptoms. Individuals who require transition from Flolan, to reduce the rate of clinical deterioration.
(TYVASO) United Therapeutics Corp. FDA approved 2009	Inhalation via nebulizer; specific to one pulmonary drug delivery system 18-54 mcg, 4 times/day	Treatment of PAH (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately individuals with NYHA Functional Class III symptoms. Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
(TYVASO DPI) United Therapeutics Corp. FDA approved 2022	Inhalation via dry powder inhaler 16-64 mcg, 4 times/day	Treatment of PAH (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately individuals with NYHA Functional Class III symptoms. Pulmonary hypertension associated with interstitial lung disease (PH-ILD;

Drug Brand Name Manufacturer FDA Approval Date	Route(s) of Administration Dose range	FDA Approved Indications
		WHO Group 3) to improve exercise ability.
(ORENITRAM) United Therapeutics Corp. FDA approved 2013	Oral Maximum dose as tolerated: 3.4-21 mg twice daily[3]	Treatment of PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately individuals with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%).
iloprost (VENTAVIS) Actelion, Ltd. FDA approved 2004	Inhalation via nebulizer; specific to one pulmonary drug delivery system 2.5 to 5 mcg, 6-9 times/day	Treatment of PAH (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness predominately included individuals with NYHA Functional Class III-IV symptoms.
Prostacyclin receptor agonists		
Selexipag (UPTRAVI) Actelion, Ltd. FDA approved 2015	Oral IV infusion (if temporarily unable to take oral therapy) Starting dose 200 mcg twice daily. Increase by 200 mcg twice weekly to maximum tolerated dose up to 1600 mcg twice daily	Treatment of PAH (WHO Group 1) to improve delay disease progression and reduce risk of hospitalization for PAH. Study establishing effectiveness had long-term follow-up and included individuals with WHO functional class II-III symptoms.
Endothelin Receptor Antagonists		
Bosentan (TRACLEER) Actelion, Ltd. FDA approved 2001	Oral 62.5 to 125 mg 2 times/day	Treatment of PAH (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness predominantly included individuals with NYHA Functional Class II-IV symptoms.
Ambrisentan (LETAIRIS)	Oral 5-10 mg/day	Treatment of PAH (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing

Drug Brand Name Manufacturer FDA Approval Date	Route(s) of Administration Dose range	FDA Approved Indications
Gilead Sciences, Inc. FDA approved 2007		effectiveness predominantly included individuals with NYHA Functional Class II-III symptoms
Macitentan (OPSUMIT) Actelion Pharmaceuticals FDA approved 2013	Oral 10 mg/day	Treatment of PAH (WHO Group 1) to delay disease progression (defined as death, initiation of IV or SC prostenoids, or clinical worsening of PAH [decreased 6-minute walk distance, worsened PAH symptoms, and need for additional PAH treatment]). Macitentan also reduced hospitalization for PAH.
Phosphodiesterase (PDE5) Inhibitors		
Sildenafil citrate (REVATIO) Pfizer Labs FDA approved 2005	Oral 20 mg 3 times/day	Treatment of PAH to improve exercise ability. August 2012: FDA recommended that Revatio not be prescribed to children (ages 1-17) for PAH. (The product has not been approved for the treatment of PAH in children).
tadalafil (ADCIRCA, TADLIQ) Eli Lilly FDA approved 2009	Oral 40 mg once/day	Treatment of PAH (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness predominately included individuals with NYHA Functional Class II-III symptoms.
Soluble Guanylate Cyclase Stimulators		
Riociguat (ADEMPAS) Bayer HealthCare Pharmaceuticals FDA approved 2013	Oral 0.5-2.5 mg 3 times/day	Treatment of PAH (WHO Group 1) to improve exercise capacity and WHO functional class, and to delay clinical worsening. The pivotal study establishing efficacy and safety for this condition predominantly included individuals with NYHA Functional Class II-III symptoms. Treatment of persistent/recurrent CTEPH (WHO Group 4) after surgical

Drug Brand Name Manufacturer FDA Approval Date	Route(s) of Administration Dose range	FDA Approved Indications
		treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.

CTEPH: chronic thromboembolic pulmonary hypertension; FDA: US Food and Drug Administration; PAH: pulmonary arterial hypertension; SC: subcutaneous; NYHA: New York Heart Association; WHO: World Health Organization.
aMean dose in a controlled clinical trial at 12 weeks was 3.4 mg twice daily. Maximum doses studied were 12 mg twice daily in a 12-week blinded study and 21 mg twice daily in an open-label long-term study

2011

In response to requests, input was received through 4 academic medical centers while this policy was under review in 2011. The input focused on the issue of combination therapy. Two of the academic medical centers disagreed with the 2010 policy statement that combination therapy is considered investigational (other than when changing from 1 medication to another). The other 2 academic medical centers had mixed input; both thought there were situations in which combination therapy is medically necessary.

2014

In response to requests, input was received through 4 academic medical centers (5 reviewers) and 1 professional pharmacy society while this policy was under review in 2014. The input focused on:

- The use of riociguat and PAH-specific medications to reduce PVR preoperatively in individuals with CTEPH who are candidates for pulmonary endarterectomy: There was consensus among reviewers that riociguat is investigational in this setting, and there also was consensus that PAH specific medications are investigational in this setting.

- The use of riociguat in individuals with CTEPH who are candidates for pulmonary endarterectomy but prefer medical treatment: Results of vetting were mixed on this question.

2016

A literature search was conducted between November 1, 2015, and November 30, 2016. Research did not yield additional evidence to prompt a change to the existing policy criteria. References section was updated with four additional articles.

2017

A literature search was conducted between November 30, 2016, and October 31, 2017. References section was updated with six additional articles. Oral Uptravi (selexipag) was added to the medically necessary policy statement.

2018

A literature search was conducted between November 1, 2017, and October 9, 2018. Research did not yield additional evidence to prompt a change to the existing policy criteria. References section was updated with additional articles. Clarified sildenafil vs. sildenafil citrate.

2019

Reviewed prescribing information for all drugs and conducted a literature search from July 1, 2018, through August 15, 2019. Identified Veletri (epoprostenol) as missing and added Veletri to policy with the same criteria as Flolan (epoprostenol). No new evidence was identified that would require changes to other drugs listed in this policy.

2020

Reviewed prescribing information for all drugs and conducted a literature search from August 1, 2019, through February 28, 2020. No new evidence was identified that would require changes to coverage criteria listed in this policy.

∞

2021

Reviewed prescribing information for all drugs and conducted a literature search from February 29, 2020, through January 1, 2021. No new evidence or guideline updates were identified that would require changes to coverage criteria listed in this policy.

2022

Added coverage for combination therapy with tadalafil and ambrisentan as first-line treatment for individuals who have WHO Functional Class Groups II and III disease. Initial combination therapy with tadalafil and ambrisentan resulted in a significantly lower risk of clinical-failure events than the risk with ambrisentan or tadalafil monotherapy. Reviewed product availability and added Tyvaso DPI (treprostinil) oral inhalation powder dosage form to the medical policy. Tyvaso DPI is a dry powder inhalation and is more portable and can be administered more quickly compared to the Tyvaso solution which requires a nebulization device. Both Tyvaso and Tyvaso DPI are administered four times daily. Updated Description and Background information for PAH. Updated Practice Guidelines and Position Statements for PAH and CTEPH.

2023

No new evidence was identified that would require changes to coverage criteria listed in this policy. Added Liqrev (sildenafil) to phosphodiesterase-5 (PDE-5) inhibitors for the indication of PAH WHO group 1 to match with the FDA label.

2024

Added sildenafil 10 mg/mL oral suspension (generic of Revatio) to phosphodiesterase-5 (PDE-5) inhibitors for the indication of PAH WHO group 1. Added coverage criteria for Winrevair (sotatercept-csrk). Added coverage criteria for Opsynvi (macitentan-tadalafil).

References

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. Dec 24 2013; 62(25 Suppl): D34-41. PMID 24355639

2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. Apr 282009; 119(16): 2250-94. PMID 19332472

3. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. Oct 2009; 30(20): 2493-537. PMID 19713419

4. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European

5. Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. Oct 2015; 46(4): 903-75. PMID 26318161

6. Archer SL. Riociguat for pulmonary hypertension--a glass half full. N Engl J Med. Jul 25 2013; 369(4): 386-8. PMID23883383

7. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. Aug 2012; 142(2): 448-456. PMID 22281797

8. Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. Nov 2015; 34(11): 1366-75. PMID 26210752

9. Anand V, Garg S, Duval S, et al. A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension. Pulm Circ. Sep 2016; 6(3): 295-301. PMID 27683606

10. Zeng WJ, Xiong CM, Zhao L, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J. Jul2012; 40(1): 67-74. PMID 22362846

11. Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. Apr 2016; 4(4): 291-305. PMID 26935844

12. McCrory DC, Coeytaux RR, Schmit KM, et al. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Rockville MD: Agency for Healthcare Research and Quality; 2013. **https://effectivehealthcare.ahrq.gov/products/hypertension-pulmonary-arterial/research**. Accessed December 24, 2023.

13. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. Oct 15 2011; 108(8): 1177-82. PMID 21864815

14. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. May 04 2010; 55(18): 1915-22. PMID20430262

15. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. Dec 01 2006; 174(11): 1257-63. PMID 16946127

16. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. Oct 2006; 28(4): 691-4. PMID 17012628

17. Vizza CD, Jansa P, Teal S, et al. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord. Sep 06 2017; 17(1): 239. PMID 28874133

18. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. Aug 2015; 46(2): 405-13. PMID 26113687

19. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy inpatients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. Oct 21 2008; 149(8): 521-30.PMID 18936500

20. Galie N, Muller K, Scalise AV, et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. May 2015; 45(5): 1314-22. PMID 25657022

21. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. Mar 15 2020;201(6): 707-717. PMID 31765604

22. Galie N, Barbera JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. NEngl J Med. Aug 27 2015; 373(9): 834-44. PMID 26308684

23. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. Sep 2004; 24(3): 353-9. PMID 15358690

24. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation. Apr 252006; 113(16): 2011-20. PMID 16636189

25. Fedullo P, Kerr KM, Kim NH, et al. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med.Jun 15 2011; 183(12): 1605-13. PMID 21330453

26. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. Jul 25 2013; 369(4): 319-29. PMID 23883377

27. Kim NH, D'Armini AM, Grimminger F, et al. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart. Apr 2017; 103(8): 599-606. PMID 28011757

28. Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. May 2015; 45(5): 1293-302. PMID 25395036

29. Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. Mar 2019; 7(3): 239-248. PMID 30477763

30. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. Feb 2003; 123(2): 338-43. PMID 12576349

31. Kramm T, Eberle B, Krummenauer F, et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg. Sep 2003; 76(3): 711-8. PMID 12963183

32. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. Jan 2010; 139(1): 85-91. PMID 19660388

33. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. Mar 2019; 155(3): 565-586. PMID 30660783

34. Wiener RS, Ouellette DR, Diamond E, et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest. Jun 2014;145(6): 1383-1391. PMID 24889436

35. Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med.Mar 15 2014; 189(6): 727-40. PMID 24628312

36. Dweik RA, Rounds S, Erzurum SC, et al. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. Feb 01 2014; 189(3): 345-55. PMID 24484330

37. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism,iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. Apr 26 2011; 123(16): 1788-830. PMID 21422387

38. Liqrev (sildenafil) [Package Insert]. Farmville, NC; CMP Pharma, Inc. Revised April 2023.

39. Winrevair (sotatercept-csrk) [Package Insert]. Rahway, NJ; Merck Sharp & Dohme LLC. Revised March 2024.

History

Date	Comments
06/25/98	Add to Prescription Drug Section - New Policy
12/21/00	Replace Policy - Policy updated; policy statement revised to include new FDA approved indication for treatment of secondary PH.
03/11/03	Replace Policy - Policy reviewed and updated with literature review; discussion of new drugs treprostinil and bosentan added. Policy retitled to reflect discussion of new drugs.
05/11/04	Replace Policy - Policy reviewed and updated; references added; no change in policy statement.
06/14/05	Replace Policy - Policy updated with policy statement revised to state that iloprost may be considered medically necessary reflecting FDA approval; references and codes added.
02/06/06	Codes updated - No other changes.
06/16/06	Update Scope and Disclaimer - No other changes.
08/08/06	Replace Policy - Policy updated and policy revised to include sildenafil as a consideration for medically necessary treatment reflecting FDA approval; references added.
08/21/06	Codes Updated - No other changes
03/10/09	New PR Policy - New PR policy, replaces BC.5.01.09. Policy statement updated to include Investigational statement relating to combination therapy and medically necessary statement regarding the prevention and/or healing of ischemic digital ulcers in individuals with severe Raynaud's phenomenon. References added. Reviewed and recommended by P&T in November 2008.
10/12/10	Replace Policy - Reviewed and recommended by OAP in August 2010 and P&T in September 2010. Policy revised with literature search; references with 2009 references renumbered. The policy statement has been updated: Tyvaso has been added to treprostinil policy statement; tadalafil (ADCIRCA) added as medically necessary; and a medically necessary statement has been added indicating all listed therapies for the prevention and/or healing of ischemic digital ulcers in individuals with severe Raynaud's phenomenon secondary to scleroderma/systemic sclerosis and who are refractory to optimized dosing of at least two conventional pharmacotherapies. No other change in policy statements.
11/10/11	Replace Policy – Policy updated with literature review; references 45 and 46 added. No change in policy statement. Reviewed by P&T September 27, 2011.

Date	Comments
11/13/12	Replace policy. Policy updated with literature search through July 2012. Policy title changed to: "Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension." Policy statement added that "use of other advanced therapies for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1), including but not limited to imatinib and simvastatin, is considered investigational." Policy statement on combination therapy reformatted as bulleted list; statement that each medication needs to be considered medically necessary was added. Policy now aligns with BCBSA 5.01.09, with an additional medically necessary policy statement allowing addressed therapies for the prevention and/or healing of ischemic digital ulcers in individuals with severe Raynaud's phenomenon secondary to scleroderma and who are refractory to optimized dosing. References updated to support policy statements. HCPCS code S0088 and ICD-10 codes added.
08/15/13	Update Related Policies. Add 5.01.545.
12/09/13	Replace policy. Policy completely rewritten to mirror BCBCSA policy 5.01.09; adding macitentan (OPSUMIT) oral (PAH/ WHO Group 1) and riociguat (ADEMPAS) (PAH/ WHO Group 1 and CTEPH/ WHO Group 4) to the list of drugs considered medically necessary. Description section updated to provide supporting information to updates in Policy. References 54-56 added. CPT code 93503 and HCPCS codes K0730, S0088, K0090, and S0155 removed; these do not apply specifically to the policy and are purely informational.
12/17/14	Annual Review. Policy updated with input from clinical reviewers; references 2, 14, and 42 updated. ICD-10 PCS codes removed; not utilized in policy adjudication.
01/05/15	Update Related Policies. Add 5.01.545.
05/12/15	Annual Review. Policy updated with literature review through February 2, 2015; references 11, 32-35, 49, 63-66, and 74 added; reference 36 updated. Oral treprostinil (Orenitram) added to medically necessary policy statement.
01/01/17	Annual Review, approved December 13, 2016. Research did not yield additional evidence to prompt a change to the existing policy criteria. References section was updated with four additional articles.
12/01/17	Annual Review, approved November 21, 2017. References section was updated with six additional articles (references 80 - 85). Oral selexipag (Uptravi) added to medically necessary policy statement. Added HCPCS code J7686. *This policy varies slightly from the BCBSA reference policy.
11/01/18	Annual Review, approved October 26, 2018. Clarified generic sildenafil and tadalafil use for PAH only. Use for ED is off-label. Literature review and updated references.
04/01/19	Interim Review, approved March 19, 2019. Added Alyq (tadalafil) to medical policy and removed Levitra (vardenafil). Organized medications to treat PAH by therapeutic class.
07/01/19	Interim Review, approved June 4, 2019. Added generic ambrisentan, bosentan and treprostinil to medical policy.

Date	Comments
10/01/19	Annual Review, approved September 5, 2019. Added Veletri (epoprostenol) to medical policy.
04/01/20	Annual Review, approved March 19, 2020. Reviewed prescribing information and conducted literature search from August 1, 2019, to February 28, 2020. No changes to coverage criteria.
02/01/21	Annual Review, approved January 21, 2021. Reviewed prescribing information and conducted literature search from February 29, 2020, to January 1, 2021. No changes to coverage criteria.
08/01/21	Coding update, Removed HCPC code S9347.
10/01/21	Interim Review, approved September 23, 2021. Added Uptravi (selexipag) IV dosage form to medical policy. Added HCPC code J3490 for new dosage form for Uptravi and updated drug indication under HCPC code J3285 from Uptravi to Veletri.
05/04/22	Minor update to related policy title 5.01.545 – changed from "Cialis (tadalafil) for Benign Prostatic Hyperplasia" to "Tadalafil Products for Benign Prostatic Hyperplasia".
10/01/22	Annual Review, approved September 13, 2022. Added coverage for combination therapy with tadalafil and ambrisentan as first-line treatment for individuals who have WHO Functional Class Groups II and III disease. Added Tyvaso DPI (treprostinil) oral inhalation powder dosage form to the medical policy. Changed the wording from "patient" to "individual" throughout the policy for standardization.
02/01/23	Interim Review, approved January 23, 2023. Added Tadliq (tadalafil) 20 mg/5 mL oral suspension to the list of PDE5 inhibitors.
06/01/23	Annual Review, approved May 22, 2023. No new evidence was identified that would require changes to coverage criteria listed in this policy.
07/01/23	Interim Review, approved June 26, 2023. Added Liqrev (sildenafil) to phosphodiesterase-5 (PDE-5) inhibitors for the indication of PAH WHO group 1 to match with the FDA label.
02/01/24	Annual Review, approved January 9, 2024. Added sildenafil 10 mg/mL oral suspension (generic of Revatio) to phosphodiesterase-5 (PDE-5) inhibitors for the indication of PAH WHO group 1. Revatio added to HCPCS code J3490.
08/01/24	Interim Review, approved July 9, 2024. Clarified that the policy statements refers to the generic version of ambrisentan and bosentan. Added coverage criteria for Winrevair (sotatercept-csrk). Added coverage criteria for Opsynvi (macitentan-tadalafil). Added HCPCS codes J3590 (Winrevair) and J8499 (Opsynvi and Liqrev).
10/01/24	Interim Review, approved September 10, 2024. The following policy changes are effective January 3, 2025, following a 90-day provider notification. Updated criteria for Remodulin (treprostinil injection) requiring an inadequate response or intolerance to generic treprostinil injection first.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.